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Abstract
This study explored the psychosocial impact of BoNT-A injections for OMD and
explored how participants judge the success of this treatment. Eight participants with OMD
participated in a single semi-structured interview. Phenomenological methods were used to
analyze the interview data into themes. Two themes and six subthemes emerged from the
analysis of the data. The first theme, Botox has changed me and my experiences, explored the
participants’ perspective of receiving BoNT-A injections and its psychosocial impact. The
second theme, What communication is like for me, explored the psychosocial impact of BoNT-A
on speech production and participation. Our results suggest that BoNT-A has a variable impact
on domains related to QoL, satisfaction with treatment, speech production, and participation.
This study adds novel information related to the psychosocial consequences of BoNT-A
treatment in the management of OMD and builds on a literature that studies the consequences
and experiences of living with OMD.

Keywords: oromandibular dystonia, BoNT-A, psychosocial outcomes, phenomenology, quality
of life, communication
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Summary for Lay Audience
Oromandibular dystonia (OMD) is a neurological disorder that may cause difficulties
with opening and/or closing of the jaw, and speech production. Furthermore, facial grimacing,
lip pursing or retraction, lingual protrusion and/or rotary movements of the tongue may also be
present. There is no cure for OMD. Botulinum toxin type-A injections (BoNT-A) is considered
to be the most effective treatment for OMD. This study explored the psychosocial impact of
BoNT-A for individuals with OMD and explored how participants judge the success of this
treatment. Eight participants with OMD participated in a single semi-structured interview.
Qualitative phenomenological methods were used to analyze the interview data into themes.
Phenomenology is a method of inquiry that allows for the exploration of the experiences of a
group of people who share a common phenomenon. In this case, the common phenomenon is the
experience of living with OMD and receiving of BoNT-A injections as treatment. Two themes
and six subthemes emerged from the analysis of the data. The first theme, Botox has changed me
and my experiences, explored the participants’ perspective of receiving BoNT-A injections and
its psychosocial impact. The second theme, What communication is like for me, explored the
psychosocial impact of BoNT-A on speech production and participation. The results of this study
suggest that BoNT-A treatment has variable impact and effect across domains related to quality
of life, expectation and satisfaction with treatment, speech production, and participation; with
some participants reporting positive effects associated with receiving injections, and others
reporting more negative or neutral impact. This research adds novel information relating to the
psychosocial consequences of BoNT-A treatment in the management of OMD and builds on a
small, but growing literature, which seeks to study the consequences and experiences of living
with OMD.

iii

Acknowledgments
I want to thank my supervisor, Dr. Allyson Page. Thank you for your constant guidance,
support, and mentorship. Thank you for providing me the opportunity to take part in such a
fantastic project. I could not have completed this thesis without your help. Thank you to my
advisory committee, Dr. Scott Adams and Dr. Carolyn Baylor, as well as Dr. Kathryn Yorkston.
Your expertise and advice throughout my project have helped tremendously in shaping my thesis
into what it is today.

Thank you to the research participants for sharing your experiences. I gained such
valuable knowledge and inspiration from you all.

To my fellow lab members, Cynthia Mancinelli and Courtney McCallum, thank you for
your positivity and encouragement.

To my friends and family, thank you for your never-ending support, and motivation
throughout this experience.

To my dad and sisters, thank you for your continuous love, support, and encouragement. I
am so lucky to have you as my support system.

Finally, to my mom, thank you. Thank you for always believing in me and continually
pushing me to never give up and keep striving to reach my goals. I am forever grateful for your
unconditional love and support.

iv

Table of Contents
Abstract ........................................................................................................................................... ii
Summary for Lay Audience ........................................................................................................... iii
Acknowledgments.......................................................................................................................... iv
Table of Contents ............................................................................................................................ v
List of Tables ................................................................................................................................ vii
List of Appendices ....................................................................................................................... viii
Chapter 1 ......................................................................................................................................... 1
1 Introduction .................................................................................................................................. 1
1.1 Dystonia ................................................................................................................................ 1
1.2 Oromandibular Dystonia ....................................................................................................... 1
1.3 Pathophysiology of OMD ..................................................................................................... 2
1.4 Clinical Characteristics of OMD .......................................................................................... 3
1.5 Speech Production Deficits ................................................................................................... 4
1.6 Treatment .............................................................................................................................. 6
1.7 Clinical Effects of BoNT-A for OMD ................................................................................ 10
1.8 Psychosocial impact of living with OMD ........................................................................... 11
1.9 Psychosocial Impact of BoNT-A for Individuals with OMD ............................................. 12
1.10 Exploring Personal Experiences Through a Qualitative Lens .......................................... 17
1.11 Rationale ........................................................................................................................... 19
1.11 Purpose.............................................................................................................................. 20
Chapter 2 ....................................................................................................................................... 21
2 Method ....................................................................................................................................... 21
2.1 Methodology ....................................................................................................................... 21
2.2 Participant Selection ........................................................................................................... 22
2.3 Participants .......................................................................................................................... 22
2.4 Procedure ............................................................................................................................ 23
2.5 Quality Criteria ................................................................................................................... 27

v

Chapter 3 ....................................................................................................................................... 29
3 Results ........................................................................................................................................ 29
3.1 Theme 1: Botox has changed me and my experiences ....................................................... 30
3.2 Theme 2: What communication is like for me.................................................................... 39
Chapter 4 ....................................................................................................................................... 49
4 Discussion .................................................................................................................................. 49
4.1 Perspective and Experience ................................................................................................ 49
4.2 Speech Production and Participation .................................................................................. 54
4.3 Limitations of the Current Study ........................................................................................ 57
4.4 Future Directions ................................................................................................................ 58
4.5 Clinical Implications ........................................................................................................... 59
Chapter 5 ....................................................................................................................................... 61
5 Summary and Conclusions ........................................................................................................ 61
References ..................................................................................................................................... 62
Curriculum Vitae .......................................................................................................................... 94

vi

List of Tables
Table 1. Characteristics of Participants with OMD ...................................................................... 23
Table 2. Interview Questions ........................................................................................................ 25
Table 3. Themes and Sub-themes ................................................................................................. 30

vii

List of Appendices

Appendix A: Letter of Information ............................................................................................... 73
Appendix B: Consent Form .......................................................................................................... 76
Appendix C: Ethics Approval Notice ........................................................................................... 77
Appendix D: Code Dictionary ...................................................................................................... 78
Appendix E: Reflexive Notes ....................................................................................................... 80

viii

1

Chapter 1
1 Introduction
1.1 Dystonia
Dystonia is a neurological movement disorder that is characterized by random,
unpredictable movements and abnormal postures that can vary in speed, duration, and amplitude
(Duffy, 2013). These unpredictable movements are the outcome of excessive co-contractions of
opposing muscles (Duffy, 2013). The movements can be present at rest, during sustained
postures, or during activity (Duffy, 2013). Dystonia can be focal (affecting one body region),
segmental (affecting more than one adjacent body region), multifocal (affecting more than one
non-adjacent body region), hemi-focal (affecting the muscles of only one side of the body), or
generalized (affecting multiple muscle regions throughout the body) (Brin, & Comella, 2004).

1.2 Oromandibular Dystonia
When dystonia is focal to the oral and facial regions, it can be characterized as
Oromandibular Dystonia (OMD) (Duffy, 2013). OMD is a rare neurological disorder with an
estimated annual incidence of 3.3 cases/million and a prevalence of 68.9 cases/million persons
(Nutt, Muenter, Aronson, Kurland, & Melton, 1988). The average age of onset is estimated to be
66 years (ranging from 40-86 years of age) with more women affected than men by a ratio of 4:1
(Nutt et al., 1988). There are six types of OMD: jaw-closing dystonia, jaw-opening dystonia,
jaw-deviation dystonia, lip dystonia, lingual dystonia (LD), or a combination of any of these.
Dystonia can result in forceful involuntary muscular contractions or abnormal postures of the
jaw, lower facial, and lingual muscles (Bakke, Larsen, Dalager & Møller, 2013).
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OMD may cause difficulties with opening and/or closing of the jaw, speech production,
and/or mastication and deglutition. Furthermore, facial grimacing, lip pursing or retraction,
lingual protrusion and/or rotary movements of the tongue may also be present (Duffy, 2013). The
dystonic contractions associated with OMD are often provoked by voluntary actions, such as
eating and speaking. This can result in difficulty managing oral intake of foods and liquids, and
can result in reduced speech intelligibility (Blanchet, Rompre, Lavigne, & Lamarche, 2005;
Dykstra, Adams, & Jog, 2007a).

1.3 Pathophysiology of OMD
OMD is associated with damage to the basal ganglia, cerebellum, and dopaminergic
system (Duffy, 2013). Neuroimaging studies suggest that the abnormalities in somatosensory
processioning and integration in the sensorimotor cortex may also play a role (Lee, 2007). OMD
is often idiopathic in nature, but also can be associated with genetic and environmental etiologies
(Lee, 2007). A number of autosomal dominant and recessive and X-linked genes have been
associated with dystonia (DYT genes) (Tarsy & Simon, 2006). Genes that are related to isolated
dystonia, where dystonia is the only disease apparent, include TOR1A/DYT1, THAP1/DYT6
and GNAL/DYT25 (Klein, 2014). In combined dystonia, where dystonia is accompanied with
other movement disorders (i.e., parkinsonism or myoclonus), the linked genes are,
GCH1/DYT5a, TH/DYT5b, ATP1A3/DYT12, TAF1/DYT3 and SGCE/DYT11 (Klein, 2014).
Recurrent, intensified forms of dystonia may be associated with PRRT2/DYT10, MR-1/DYT8
and SLC2A1/DYT18 genes (Klein, 2014).
The DYT12-ATP1A3 gene is linked to rapid-onset dystonia-parkinsonism. It arises in
adolescence or young adulthood in response to physical or mental stress (Klein, 2014). The
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DYT12-ATP1A3 gene is inherited in an autosomal dominant manner, with reduced penetrance
(where an individual known to carry the dominantly inherited mutated gene may not show
clinical evidence of the condition) (Klein, 2014). As a result, dystonic spasms (primarily in the
upper limbs), orofacial dystonia, dysarthria, dysphagia, and slow movements may arise as
symptoms (Klein, 2014). The DYT6-THAP1 gene is another gene that is linked to adolescentonset dystonia. This gene has features of focal and generalized primary dystonia and is inherited
in an autosomal dominant manner with penetrance (where an individual that is carrying the
dominantly inherited gene exhibits symptoms of the condition) (Klein, 2014).
The secondary form of dystonia can develop due to environmental factors, long-term
neuroleptic drugs, neurologic diseases, brain injuries, and peripheral traumas (Lee, 2007). It may
also arise as the result of surgical complications, and neurodegenerative diseases and disorders
(Lee, 2007). Long-term use of a dopamine receptor blocking medication (i.e., levodopa) can
decrease the neurotransmission of dopamine, resulting in increased dopamine D2 receptor
sensitivity. This increase can lead to a decrease in the inhibitory pathway resulting in dystonia
(Lee, 2007). Dystonia may also arise from traumatic brain injuries, affecting the putamen or
thalamus (Lee, 2007). Peripheral trauma, such as dental trauma, or trauma to cranial peripheral
nerves or nerve roots, can lead to changes in the basal ganglia and may also be associated with
dystonia (Jankovic, 2009; Lee, 2007).

1.4 Clinical Characteristics of OMD
The contraction of agonist and antagonist muscles, with overflow of unwanted muscle
contractions into the adjacent muscles, results in the dystonic contractions associated with OMD
(Lee, 2007). The dystonic movements can either be slow or rapid, and can change during
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different activities or postures (Tarsy & Simon, 2006). The abnormal postures can occur during
voluntary activities and some task-specific activities; this occurrence is referred to as action
dystonia (Tarsy & Simon, 2006).
Alterations of orofacial musculature arise as a result of the contractions and abnormal
postures associated with OMD (Sinclair, Gurey, & Blitzer, 2013). A study by Papapetropoulos
and Singer (2006), indicated that dystonic-eating dysfunction was a common problem amongst
individuals with OMD. Over half of the patients in the study with eating dysfunction reported
pain due to the dysfunction and significant weight loss (Papapetropoulos & Singer, 2006). A
study by Charles, Davis, Shannon, Hook and Warner (1997), also reported that their participants
with OMD presented with reduced and painful masticatory and swallowing capabilities
characterized by tongue biting and food being pushed from the oral cavity while chewing.
Excessive dental wear, dental fractures, and trauma of the lips, gums, and tongue may also be
associated with jaw-closing dystonia, whereas jaw-opening dystonia may be accompanied with
temporomandibular joint overload (Bakke et al., 2013).

1.5 Speech Production Deficits
Speech production can be adversely impacted in those with OMD, resulting in dysarthria
(Darley, Aronson, & Brown, 1969a). Dysarthria is a collective name for a group of speech
disorders resulting from disturbances in muscular control over the speech mechanism, due to
damage of the central or peripheral nervous system (Darley et al., 1969a). Dysarthria reflects
abnormalities in strength, speed, range, steadiness, tone, or accuracy of movements required for
the respiratory, phonatory, resonatory, articulatory, or prosodic aspects of speech production
(Duff, 2013). More specifically, OMD can produce a slow hyperkinetic dysarthria (Darley et al.,
1969a).
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Hyperkinetic dysarthria’s are associated with disruption within the basal ganglia control
circuit (Duffy, 2013). Imprecise consonant articulation, vowel distortion, and irregular
articulation breakdowns are common speech impairments that can arise as a result (Darley,
Aronson, & Brown, 1969b). The distinctive speech characteristics associated with hyperkinetic
dysarthria can result in a reduction of speech intelligibility (Darley et al., 1969b; Dykstra, Hakel,
& Adams, 2007b). Yorkston, Strand and Kennedy (1996), define speech intelligibility as “the
degree to which the acoustic signal is understood by the listener” (p. 55). Yorkston, Dowden and
Beukelman, (1992) broadly define speech intelligibility as the “understandability of speech” (p.
265).
Dykstra and colleagues (2007a), studied the speech intelligibility of an individual with
focal lingual dystonia, and analyzed acoustic and perceptual aspects of intelligibility. The results
showed that dystonic movements of the lingual musculature were associated with palatal
fricatives being perceived as more fronted alveolar fricatives (e.g. //->/s/), which contributed to
reductions in speech intelligibility. Another study by Golper, Nutt, Rau and Coleman (1983),
examined the speech characteristics of patients with Meige’s syndrome, which is OMD with
blepharospasm (involuntary closure of the eyelids). The results showed that a patient with severe
lingual dystonia, and reduced speech intelligibility, had difficulty with frontal tongue placement
(Golper et al., 1983). Dykstra, Adams and Jog (2005) also concluded that abnormal lingual
protrusion and elevation could cause speech intelligibility deficits in individuals with focal
lingual dystonia, or OMD that affects the tongue.
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1.6 Treatment
As there is no cure for OMD, practitioners aim to provide treatments that focus on
reducing the dystonic contractions of the orofacial musculature to allow for improvement in
functional speech, masticatory capabilities, swallowing, orofacial esthetics, and quality of life
(QoL) (Dykstra & Adams, 2009; Dykstra et al., 2007a). These varied treatment approaches can
be characterized broadly into the following categories: pharmacological, sensory, prosthetic,
behavioural, and medical via chemodenervation.

Pharmacological. Anticholinergics, benzodiazepines, baclofen, and tetrabenazine are
drugs that deplete dopamine and block dopamine receptors (Tintner, & Jankovic, 2002).
Although these drugs have been found to be beneficial in some patients, they are not a preferred
form of treatment for focal dystonias. In treating dystonia, these medications have been shown to
provide only modest improvement and are associated with frequent side effects (Tintner, &
Jankovic, 2002). These medications are most effective in cases of widespread dystonia (Karp,
Goldstein, & Chen, 1999). The most tolerated medication for treating OMD is Clozapine (Karp
et al., 1999). Clozapine is different from other drugs in its interactions with neurotransmitter
receptors and its range of side effects (Karp et al., 1999). Clozapine acts on the dopaminergic
pathways by binding to and increasing dopamine receptor density in the basal ganglia. This
reduces the over-activity of the direct pathway, thereby reducing the dystonic contractions (Karp
et al., 1999).

Sensory. A sensory trick, or “geste antagoniste”, is a method some patients with OMD
use to temporarily relieve dystonic symptoms (Yoshida, 2018). Sensory tricks include motor
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tricks (voluntary movement input), imaginary tricks (imagining the performance of their own
sensory tricks or other mental imaging), forcible tricks (maneuvers similar to sensory tricks, but
require the use of force, and are always antagonistic to the direction of the dystonia) and reverse
sensory tricks (sensory trick-like stimuli that result in worsening of dystonia) (Ramos, Karp, &
Hallett, 2014; Yoshida, 2018). Sensory tricks can be physical, proprioceptive, visual, auditory,
and thermal stimuli (Yoshida, 2018). Sensory tricks are highly individualized, but common
examples can include holding an object in the mouth, chewing gum, or touching a certain area of
the face, such as the chin, cheek, or eyelid to temporarily relieve dystonic symptoms (Duffy,
2013). The mechanisms behind sensory tricks are unknown (Ramos et al., 2017; Yoshida, 2018).
Yoshida (2018) studied 128 individuals with various presentations of OMD. Participants
were fit with a splint designed to elicit a sensory trick in order to reduce dystonic movements.
The results of this study revealed that individuals with jaw-closing dystonia, as compared to
other dystonia types (i.e., lingual, jaw-opening, labial, jaw deviation), derived the most benefit
from the splint when used as an elicitation of a sensory trick. Additionally, participants with
intraoral sensory tricks (inserting an object or food into the oral cavity) found the splint more
effective than patients with extra-oral sensory tricks (tactile facial stimulation, i.e., touching the
chin or teeth with a finger or hand).
Teemul, Patel, Kanatas, and Carter (2016), studied six patients with OMD, and found that
their participants reported triggers, such as stress, talking, chewing, and praying resulted in
increased dystonic activity. Yoshida (2018), showed that temporary relief, for some, from such
symptoms was found by gently touching the lips, chin, teeth, or jaw with a handkerchief or
mask; chewing gum; talking; biting on a toothpick or tobacco; or placing a finger underneath the
chin. Sensory tricks tend to lose effectiveness over the course of the dystonia, even to the point
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of disappearing completely (Ramos et al., 2014).

Prosthetic: bite-block. A bite block is a device that can come in many shapes, sizes and
textures and can range from an acrylic block to a block made from dental impression material or
putty (Seikel, Drumright, & King, 2016). It is placed between the upper and lower teeth to assist
with jaw stability and positioning. Bite blocks can improve facial appearance, articulatory
precision, and hyperactive movements associated with hyperkinetic dysarthria (Dworkin, 1996;
Goldman & Comella, 2003). Bite blocks can prevent enamel wear, decrease the load on
oromandibular joints, and improve chewing function (Blanchet et al., 2005). They may also
provide sensory information for the correct placement of other articulators (Lee, 2007). Dworkin
(1996) conducted a study where bite-blocks were utilized in two individuals with oromandibular
dystonia. Initially, both participants were judged to have moderately reduced intelligibility
(Dworkin, 1996). However, once the bite blocks were in place, speech intelligibility was judged
as near normal (Dworkin, 1996). It was hypothesized that the bite-block neutralized the dystonic
activity by facilitating postural balance and motor stability of the mandible (Dworkin, 1996).

Behavioural. The goal of behavioral therapy is to improve the coordination of
articulators for those with OMD (Goldman & Comella, 2003). A study by Netsell and Cleeland
(1973) used EMG biofeedback (auditory) with an individual with dystonia affecting the upper
lip. Surface electrodes were placed over muscles that were contracting to retract the upper lip,
and the individual was presented with a tone whose frequency was equivalent to the voltages
recorded from the electrodes (Netsell & Cleeland, 1973). The individual’s task was to
concentrate on lowering the tone, which served to decrease the dystonic activity in the upper lip
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(Netsell & Cleeland, 1973). This behavioural technique helped the participant learn to control
and reduce her labial muscle activity (Netsell & Cleeland, 1973).
Speech-language pathologists (SLPs) may also focus on providing patients with
management strategies. For example, a speech-language pathologist may teach dyadic strategies
or verbal interaction strategies to improve communication. These strategies may include: getting
the listener’s attention before speaking, making the context and topic clear, maintaining eye
contact, using gestures whenever possible, informing the listener that they wish to know
immediately when they have not been understood, reiterating an utterance or word when an
abnormal movement pattern has potentially interfered with communication and modifying the
communicative environment to improve visual and auditory acuity (Duffy, 2013). Similarly, the
listener should be attentive to the speaker and inform the speaker immediately of any
misunderstandings (Duffy, 2013). Although these techniques are not specific to OMD, they can
improve communicative interactions, and these techniques can be used concurrently with other
forms of treatment.

Deep Brain Stimulation. Deep brain stimulation (DBS) is a surgical procedure where a
stimulator is implanted in the brain. This implant delivers electrical stimulation to the area of the
brain affected by dystonia, such as the globus pallidus or the thalamus (Krauss, Yianni, Loher, &
Aziz, 2004). The DBS stimulator suppresses the electrical signals causing the dystonia, thereby
lessening the dystonic symptoms (Krauss et al., 2004). DBS has been proven to be most
beneficial for generalized and segmental dystonia. Further research is required to determine if
this treatment option is effective for focal dystonias, such as OMD (Krauss, et al., 2004).
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Chemodenervation.To date, chemodenervation is the primary therapeutic treatment for
patients with OMD, and this is achieved via botulinum toxin type-A injections (BoNT-A)
(Teemul et al., 2016). BoNT-A is considered to be the most effective treatment for OMD
(Kazerooni & Broadhead, 2015). BoNT-A causes temporary paralysis by blocking the
presynaptic release of acetylcholine at the neuromuscular junction (Simpson, 1981). BoNT-A
injections produce temporary chemical denervation, paralysis, muscle atrophy, and local
weakness, which help reduce muscle contractions (Giladi, 1997). It takes about one to three days
for the weakness induced by the toxin to appear. By two weeks, a marked effect is present
(Blitzer & Sulica, 2001). The effects of BoNT are limited in duration, lasting three months on
average (Blitzer & Sulica, 2001). At that time the axon terminal begins to sprout and form new
synaptic contacts on adjacent muscle fibers. For this reason, the effects of BoNT-A are limited in
duration (Simpson, 1989). Depending on the individual and the affected area, the effects of
BoNT-A could last for two to three months (Giladi, 1997).

1.7 Clinical Effects of BoNT-A for OMD
Jankovic, Schwartz, and Donovan (1990) reported that injections of BoNT-A into the
masseter, temporalis and geniohyoid, resulted in a reduction of dystonic spasms, and an
improvement in chewing and speech, in approximately 73% of their patients with OMD. BoNTA injections have been shown to reduce pain caused by dystonic contractions (Jankovic, 2018;
Khan, Anwer, Eliav & Heir, 2015), and can improve orofacial aesthetics by reducing dystonic
activity (Merz, Deakin & Hawthorne, 2010). There is some evidence to suggest that bilateral
injections of BoNT-A into the intrinsic muscles of the tongue can reduce dystonic activity and
improve speech intelligibility. This finding was demonstrated in an individual with focal lingual
dystonia (Dykstra et al., 2007a). Although there is an empirical literature demonstrating

11
improvement following BoNT-A injections, there can be side effects to this treatment. A study
by Blitzer, Brin, and Fahn (1991), suggested that injections in the tongue for treatment of lingual
dystonia increased the potential for dysphagia and aspiration. Other side effects of BoNT-A
include weakness, mild dysarthria, dry mouth, and difficulty chewing and swallowing (Goldman
& Comella, 2003; Gn & Ng, 2017). A study by Nastasi, Mostile, Nicoletti, Zappia, Reggio, and
Catania (2016), found that no significant associations were discovered between the amount of
years of receiving BoNT therapy and the injected muscles or the total dose injected. These
results were similar to the findings of Bhattacharyya and Tarsy (2001) and Charous and Comella
(2011). This suggests that the therapeutic benefit of BoNT-A is independent of the symptom
duration prior to treatment, the treatment duration, or the frequency of the injections. The patient
benefits from BoNT-A injections were maintained years into treatment (Bhattacharyya & Tarsy,
2001).

1.8 Psychosocial impact of living with OMD
The term ‘psychosocial’ derives its origin from the World Health Organization’s (WHO)
definition of health as ‘a state of complete physical, mental, and social well-being, and not
merely the absence of disease and infirmity’ (WHO, 1948). Psychosocial impact is defined as
“the effect caused by environmental and/or biological factors on individual’s social and/or
psychological aspects” (de Oliveira, Buchain, Vizzotto, Elkis & Cordeiro, 2013).
Psychosocial factors or variables include those that reflect individual responses to disease and
even in some cases indicators of the social context itself (Martikainen, Bartley & Lahelma,
2002). They can also be altered based on the social contexts that they exist in (Martikainen et al.,
2002). This can include examining an individual’s experience as the result of a health condition
and his/her appraisal of QoL (Martikainen et al., 2002). A diagnosis of OMD can result in
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alterations to psychosocial functioning. For example, Bakke et al., 2013 found that oral
dysfunction arising from OMD resulted in social embarrassment, reduced QoL, and depression.
Charles and colleagues reported that their patients with dystonia felt lonely and helpless, leading
to social isolation (Charles et al., 1997). Finally, Page and colleagues (2017) reported that 8
participants with OMD self-reported reductions to QoL related to communication, with
socialization being an area most affected (Page, Siegel & Jog, 2017).
A study by Papapetropoulos and Singer (2006), also explored how individuals with OMD
experience daily living. The results of this study found that eating dysfunction associated with
OMD resulted in social embarrassment, especially when accompanied by drooling or choking
(Papapetropoulos & Singer, 2006). In another study that examined long-term management of
treatment using botulinum toxin in patients with OMD, Sinclair et al., (2013), found that
alterations to orofacial aesthetics, resulting from OMD was associated with reductions in
perceived QoL. A study by Nastasi et al. (2016) found that individuals with lingual dystonia
reported social disabilities that impacted daily activities, such as talking and eating.
Dykstra and colleagues have reported that individuals with OMD have reduced
communicative participation, communicative effectiveness, and communication-related QoL
relative to control participants (Dykstra, Domingo, Adams & Jog, 2015; Page & Siegel, 2017;
Page et al., 2017). Furthermore, several individuals in Bhattacharyya and Tarsy’s (2001) study
stated that they had difficulty securing employment because employers perceived their speech or
movement patterns as abnormal and potentially offensive to customers.

1.9 Psychosocial Impact of BoNT-A for Individuals with OMD
There is a small, but growing literature, which has investigated how BoNT-A injections
impact psychosocial functioning in a number of health conditions, yet there still remains a
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fundamental gap in our understanding of this construct as it relates to OMD. It has been
suggested that the relatively sparse empirical literature exploring psychosocial outcomes could
be the result of the rarity of OMD and the resultant difficulties in recruiting research participants
(Charous & Comella, 2011). Several studies have examined the impact of BoNT treatment on
QoL outcomes for cervical dystonia, but little information is available on the impact of treatment
in OMD (Bhattacharyya & Tarsy, 2001).
Bhattacharyya and Tarsy (2001), addressed the gap in the literature and examined how
BoNT injections impact QoL in dystonias of the head and neck. The Glasgow Benefit Inventory
(GBI; The Glasgow Health Status Questionnaires Manual, 1998) was used to quantify the health
benefit of treatment of BoNT in participants with spasmodic dysphonia (SD) and OMD. The
GBI is a generic quality of life questionnaire designed for measuring outcomes following
otolaryngologic interventions (Robinson, Gatehouse & Browning, 1996). The GBI measures
quality of life in three domains: social, general, and physical. Results of the Bhattachartta and
Tarsy (2001) study revealed that participants with OMD and SD gained significant benefit within
the social support and physical health domains from therapy with BoNT, although patients with
OMD had a lower social support sub-score in comparison to patients with SD (Bhattacharyya &
Tarsy, 2001).
Dykstra and colleagues (2007a) case study evaluating the impact of BoNT-A injections
on speech intelligibility and activity and participation restrictions in an individual with focal
lingual dystonia found prominent differences across outcome measures between pre-BoNT-A
and post-BoNT-A treatment. For example, results from the Voice Activity and Participation
Profile (Ma & Yiu, 2001) showed improvements in the participants self-perception of the
severity of her speech problem, the effect on her job, and daily and social communication
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following BoNT-A injections. Prior to treatment, the participant reported a loss of employment,
reported communicative and social avoidance behaviors, embarrassment, reduced self-esteem,
and reduced self-image. Following treatment with BoNT-A, a positive difference was observed
in the participants activity and participation limitation scores (Dykstra et al., 2007a). The
participant also reported that she felt minimal to no restriction in activity and participation
relating to her job and her social communication following BoNT-A injections. Overall, this
study demonstrated that BoNT-A treatment significantly improved activity and participation
scores, and QoL of the individual studied. This case study highlighted the importance of
examining the impact of speech disorders resulting from dystonia on an individual's daily
functioning in the context of their personal, social, and environmental settings.
Charous and Comella (2011) conducted a study examining the effects of BoNT injections
on QoL for patients with jaw-opening dystonia. Similar to Bhattacharyya and Tarsy’s (2001)
study, Charous and Comella (2011) used the GBI as their primary outcome measure. The results
of the GBI total score and GBI sub-scores following BoNT injections showed improvement and
indicated that no patients experienced negative impacts from receiving BoNT injections
(Charous & Comella, 2011). Charous and Comella’s (2011) study found improvements in QoL
for all participants post-injection. Patients reported feeling more optimistic, less embarrassed,
more social, and generally felt better about themselves as a result of the injections. Physical
disturbances, as a result of dystonia, were also improved due to the BoNT injections. However,
the psychosocial gains resulting from BoNT injections were found to be far more significant than
the gains to physical well-being (Charous & Comella, 2011).
Merz et al., (2010) was the first research group to develop a disease-specific, patientreported outcome measure, validated for patients with OMD. The Oromandibular Dystonia
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Questionnaire (OMDQ-25) was created to measure health-related quality of life in individuals
with OMD. It includes 25 items that are divided into five subscales: general, psychosocial
functioning, cosmetics, speech, and eating dysfunction. Each of the 25 items is rated on a fivepoint scale with different grades of impairment: never, seldom, sometimes, often, and always
(Merz et al., 2010). Based on a sample of 30 participants with OMD, Merz and colleagues
evaluated the OMDQ-25 at pre-treatment and then at four and eight weeks after BoNT-A
treatment. This study found that the cosmetic sub-score demonstrated the greatest difference preand post-BoNT-A injections. This result indicated that the patients were highly sensitive to their
outer appearance (Merz et al., 2010). Results also demonstrated that following BoNT-A
injections, individuals with OMD showed a large benefit in scores related to psychosocial
functioning, speech, and eating.
Nastasi et al. (2016) studied the effect of BoNT treatment on QoL in patients with
isolated lingual dystonia and OMD affecting the tongue. This study aimed to investigate the
impact of BoNT on the QoL of patients with prominent lingual dystonia using the OMDQ-25 to
identify clinical and BoNT treatment-related factors that could be associated with better
outcomes regarding QoL. The response to BoNT therapy was based on both the OMDQ-25
questionnaire and clinical interviews. Nastasi et al., (2016) found that in both LD and OMD
affecting the tongue, QoL was severely affected prior to treatment. However, following BoNT
treatment, there was a positive change in total OMDQ-25 scores, demonstrating a significant
benefit in overall QoL. These results were seen in patients with LD four weeks after treatment
and the benefit to improved QoL persisted after eight weeks. The analysis of the sub-scale scores
demonstrated an improvement in many aspects of QoL (Nastasi et al., 2016). The smallest
changes were observed in the functional eating category suggesting that the complex and
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coordinated process of eating has the least response to the BoNT injections (Nastasi et al., 2016).
Dykstra, Domingo, Adams, and Jog (2015) evaluated sentence intelligibility and selfreported communicative effectiveness of 10 participants with OMD at two time points over the
course of a BoNT treatment cycle. Communicative effectiveness was measured using the
Communicative Effectiveness Survey (CES) (Donovan, Velozo, & Rosenbek, 2007; Hustad,
1999). Communicative effectiveness is defined as a person’s ability to successfully communicate
messages in home and community settings (Hustad, 1999). Evaluating communicative
effectiveness can provide important information regarding the self-perception of an individual’s
communication in various social contexts and it can facilitate broader outcome measurements
(Dykstra et al., 2015). The results of the Dykstra et al., (2015) study showed significant
differences in speech intelligibility and self-ratings of communicative effectiveness between
control participants and participants with OMD (Dykstra et al., 2015). However, there were no
significant differences in speech intelligibility or self-rated communicative effectiveness
observed over the course of the BoNT-A treatment cycle for the participants with dystonia
(Dykstra et al., 2015). However, when the group of participants with OMD were looked at based
on type of dystonia, there were suggested trends. The participants with dystonia, predominantly
affecting the lingual and, to some extent, the labial musculature, appeared to demonstrate a trend
for improving speech intelligibility scores and self-ratings of communicative effectiveness
following BoNT-A (Dykstra et al., 2015). On the other hand, participants who presented with
predominantly jaw involvement had speech intelligibility scores and self-ratings of
communicative effectiveness that had a tendency to decrease post-BoNT-A injections (Dykstra
et al., 2015).
Page and colleagues (2017) also conducted a study that examined self-rated
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communication-related quality of life (CR-QoL) in 8 control participants and 8 individuals with
OMD and dysarthria who were receiving therapeutic BoNT-A injections. The American SpeechLanguage-Hearing Association’s Quality of Communication Life Scale (ASHA QCL) was used
to assess CR-QoL (Paul, Frattali, Holland, Thompson, Caperton & Slater, 2004). The ASHA
QCL is an 18-item questionnaire rated on a 5-point scale (Paul et al., 2004). The ASHA QCL
assesses the impact of a communication disorder on an individual’s personal relationships, social
life, autonomy, well-being, and participation in educational, work, social, and leisure activities
(Paul et al., 2004). The results of the study showed that participants with OMD rated CR-QoL
lower, as compared with control participants across all ASHA QCL domains/subdomains. The
results also indicated that participants with OMD did not rate CR-QoL significantly different
over the course of the BoNT-A treatment cycle.

1.10 Exploring Personal Experiences Through a Qualitative Lens
Qualitative researchers study people in their natural setting, attempting to make sense of,
or to interpret, phenomena in terms of the meanings people attribute to them (Denzin & Lincoln,
2011). Qualitative methodology places participant as the “experiencers” and puts them in the
position of the expert throughout the research process (Wilding & Whiteford, 2005). Participants
in qualitative research are seen as active agents, who are not only describing their life events, but
are actively negotiating and reconstructing their story by choosing, interpreting and emphasizing
different aspects of their experiences (Sallinen, Kukkurainen, Peltokallio, Mikkelsson &
Anderberg, 2012). On the contrary, the researcher in qualitative research is placed in the position
of the learner, where the aim is to understand and interpret the phenomena at hand (Wilding &
Whiteford, 2005). These roles in the process of qualitative research result in collaborative

18
dialogue, which produce a genuine representation of participant’s experiences (Wilding &
Whiteford, 2005). There are varying methodologies and paradigms within qualitative research.
Common methodologies include; grounded theory, narrative research, ethnography, and
phenomenology, each with varying aims and results. Grounded theory aims to create a
theory based on the phenomena at hand (Glaser & Strauss, 1967). Another methodology,
Narrative research, aims to represent experiences through individual’s stories and portray the
complexity of human experiences. The narratives or stories that individuals share can be used as
a means to study a research question (Riessman, 2008; Riessman, 1993). Ethnography aims to
promote an understanding of why people behave as they do, to reveal culture as shared
knowledge and as acquired social behavior (Hammersley, & Atkinson, 1995). Lastly,
Phenomenology is a method of inquiry that allows for the exploration of the experiences of a
group of people who share a common phenomenon (Dowling, 2007). Each methodology can be
underpinned by varying world views called paradigms. Guba and Lincoln (2004) acknowledge
four different paradigms. The positivist and post-positivist paradigms, both work within
objective, realist approaches and accept one reality. The critical paradigm aims to use
naturalistic, subjectivist methodologies and agrees that there are multiple realities, which are
structured and shaped by power relations that are historically and socially constructed. Each of
these methodologies and paradigms allow for an in-depth understanding of participants personal
experiences and perspectives and provide insight that is otherwise difficult to obtain using a
quantitative lens. The constructivist and interpretive paradigms, take on more of naturalistic,
relativist stance, which recognizes multiple meanings and subjective realities. A constructivist
view emphasizes that researchers co-construct data together with the participants. An
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interpretivist paradigm aims to describe, understand and interpret participants’ experiences
(Tuohy, Cooney, Dowling, Murphy & Sixsmith, 2013).
In the current study, interpretive phenomenology was employed to understand the
multiple realities of living with OMD and receiving BoNT-A injections. Interpretive
phenomenology allows for the exploration of rich, multilayered, intangible, and dynamic
phenomena in aspects of an individual’s everyday life (Wilding & Whiteford, 2005).
Phenomenology takes the participants voice and experience primarily into account to allow for
new findings. New findings may also emerge as a result of the phenomenological notion that the
data itself should guide the nature and form of the study for the researcher (Dowling, 2007).
Phenomenology has been upheld as the approach of choice in areas in which there is little
published material, or where areas need to be described in more depth (Wilding & Whiteford,
2005).

1.11 Rationale
There is a relatively robust empirical literature that has investigated the pharmacological
benefit of BoNT-A injections in dystonia in general (Bhattacharyya & Tarsy, 2001). In contrast,
there is a relatively sparse, but growing empirical literature that has explored BoNT-A therapy in
OMD research using patient-reported outcome measures (questionnaires), such as perceived
QoL, communicative participation, and effectiveness of treatment from a patient perspective.
The problem with questionnaires is that they do not allow an in-depth or individualized
exploration of what factors and issues might be underlying the participants’ responses.
Nevertheless, the emerging research is important because it has provided the rationale to explore
more fully the impact of BoNT-A injections on psychosocial outcomes, especially in the context
of impaired speech production resulting from OMD. What remains unexplored in the study of
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OMD is an understanding of the impact of BoNT-A injections from the perspective of the
individual with OMD, in their own words. Each individual will perceive the same phenomenon
in different ways and bring forth his or her lived experiences, specific understandings, and
historical backgrounds (Finlay, 2002). These individualized experiences are complex to research
using quantitative research methods. On the contrary, qualitative research methods acknowledge
a subjectivist view of reality based on context and personal experience (Wilding & Whiteford,
2005). Through a subjective lens, qualitative research methods can provide an understanding of
each individual’s perspective (Creswell, 2014). These experiences and insights can highlight the
perspective of individuals living with OMD. Gaining an authentic perspective of the in-depth
experience of living with OMD can inform a greater understanding of the depth and detail of
individual experiences, determine if patient reported outcome measures are capturing all relevant
information or if other patient-reported outcomes should be explored, and finally, qualitative
inquiry can aid in the interpretation of questionnaire responses gathered clinically. Acquiring the
participants’ perspective can also serve to inform meaningful indicators of treatment success and
provide much needed insight into living with this diagnosis.

1.11 Purpose
The purpose of this study was to obtain a self-reported account of the psychosocial
consequences of BoNT-A injections for individuals living with OMD. Using qualitative,
phenomenological methodology, this study explored how participants judge the success of
BoNT-A treatment based on the psychosocial issues relevant to them. By understanding the
insider’s perspective, it is anticipated that this knowledge will help to inform the clinical
management of individuals with OMD and associated dysarthria.
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Chapter 2
2 Method
2.1 Methodology
Interpretive phenomenological qualitative research methods were used to obtain a selfreported account of the experience of living with OMD and receiving BoNT-A treatment.
Phenomenology is a method of inquiry that allows for the exploration of the experiences of a
group of people who share a common phenomenon (Dowling, 2007). In this case, the common
phenomenon is the experience of living with OMD and receiving of BoNT-A injections as
treatment. Phenomenological research is based on the principle of lived experiences (Dowling,
2007). Lived experiences are the events that naturally occur in the lives of a specific cohort
(Dowling, 2007). It is a method of inquiry that offers a way of methodically studying and
learning about phenomena that are typically difficult to observe or measure (Wilding &
Whiteford, 2005).
The interpretive phenomenological approach does not require researchers to bracket their
own preconceptions or theories during the research process (Lowes & Prowse, 2001). The
research process instead includes bridling, which was employed in this study. Bridling
acknowledges that researchers cannot help but bring their involvement and fore-understandings
into the research (Finlay, 2002). The interpretive team acknowledges any assumptions that could
both influence the researcher’s conduct of interviews and observations, as well as the whole
team’s interpretations (Crist & Tanner, 2003). It is expected that an interpretive
phenomenological approach will allow for the generation of a thorough description of the
experience of living with OMD and receiving of BoNT-A injections as treatment, in the words of
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the individuals who live it.

2.2 Participant Selection
The inclusion criteria included that all participants could read, speak, and understand
English. The recruitment was limited to an age range of 25 to 80 years. This age range was
chosen to represent a wide range of the adult population and to properly capture the average age
of onset of OMD (66 years; range of 40 – 86 years). All participants were receiving BoNT-A
injections to manage symptoms of OMD. There was no exclusion criterion regarding the type of
OMD (i.e., lingual, jaw-opening, jaw-closing, mixed) that each individual presented with. In
adherence with phenomenological guidelines, the inclusion criteria warranted a sample of
participants that all shared the experience of living OMD, in order to reveal the array of lived
experiences for this particular clinical population (Patton, 2002).

2.3 Participants
Eight participants (n=8) diagnosed with OMD participated in this study. The current
study was part of a larger study that examined speech intelligibility and communicative
participation in the same group of participants (see Dykstra et al., 2015; Page et al., 2017). In
total there were three females and five males (age range: 44-80 years; mean age: 68 years), with
an average OMD onset of 10.4 years. Participants were recruited from a specialized Movement
Disorders Clinic, in South Western Ontario. The participants recruited were receiving therapeutic
BoNT-A injections (Botox® or Xeomin®) to manage their symptoms of OMD. All participants’
demonstrated hyperkinetic dysarthria and reduced speech intelligibility as judged by an
experienced speech-language pathologist (A.P.) and had no other speech or hearing impairments.
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Table 1 describes the characteristics of each participant.
The investigator explained the nature of the study as well as provided each participant
with a letter of information (Appendix A) and a consent form (Appendix B) to sign prior to
participating in the study. This study was approved by the Health Sciences Research Ethics
Board at Western University in London, Ontario (Appendix C).

Table 1. Characteristics of Participants with OMD
Participant
Sex Age
ID*

OMD
Duration
(years)

Type/ location
Of OMD

SIT (%)
Number of Years
Receiving
PrePostBoNT-A
BoNT-A BoNT-A

GM

M

69

4

Meige’s (labial)

3

94.36

94.36

ST

F

78

2

jaw opening

3 months

97.82

94.00

NF

F

60

10

lingual

8

90.91

98.36

JR

M

44

2

Meige’s (pouting,
jaw closure)

3 months

96.54

95.27

FI

F

69

21

jaw closure

21

91.82

93.82

SP

M

78

13

lingual, jaw
closure

11

95.27

88.55

EP

M

80

23

Meige’s (jaw
opening, closure)

22

94.00

90.55

BR

M

68

8

jaw closure

3

96.73

96.73

* Initials are fictitious to protect the identity of participants
-Pre-BoNT-A refers to a time period of 3 months after the last injection cycle to correspond to a ‘wearing off’ period
of BoNT-A
- Post-BoNT-A refers to a time period of 5 weeks after injection to correspond to ‘peak’ therapeutic response of
BoNT-A
-Please see Dykstra, Domingo, Adams, & Jog (2015) for a description of sentence intelligibility scores
(Intelligibility data was collected from the same study participants as part of a larger study)
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2.4 Procedure
Interviews. The eight study participants participated individually in one face-to-face
interview lasting approximately 60-90 minutes. Interviews were scheduled at five weeks postBoNT-A injection to correspond with the peak effectiveness of the BoNT-A. Interviews were
conducted in a private room by the primary researcher (A.P), who was not involved in the
clinical care of the participants. The participants guided the phenomenological interviews to the
topics they found relevant (Table 2). The researcher encouraged participants to talk about their
experiences, feelings, and to provide stories (Table 2). The questions were expanded upon by
each participant and on occasion reiterated by the primary researcher for clarification. The
researcher also asked additional questions, when needed, to clarify points or to obtain more
information (Table 2). The interviews were audio recorded and transcribed verbatim. If the
researcher did not understand a word or sentence spoken by a participant during the interview,
she asked for clarification and repetition to ensure correct understanding and meaning. It is
anticipated that phenomenological interviews will produce a detailed account of the experience
of living with OMD and receiving BoNT-A treatment, in the words of the persons who live it.
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Table 2. Interview Questions
The interviews were guided by six general questions:
The researcher encouraged participants to talk about their experiences, feelings, and provide
stories or anecdotes.
Primary Questions:
The researcher asked additional questions as needed to clarify
points or to seek additional information. These questions may have
included:
1) How do you
feel your Botox
treatment has
helped you?
2) Has using
i) Do you think you
Botox affected
would have been
your ability to
able to do exactly
do the things
the same things, the
you want to do?
same way you’re
doing it now, had
you not been using
Botox?
3) Have you
i) Have you noticed
ii) Have you noticed iii) If yes, are the
noticed changes
any changes in your
any differences
differences you
in your speech
speech as far as the
between before
noticed from
since using
clarity or the
you get your
using Botox
Botox?
understandability?
Botox and after
important to
you get your
you?
Botox?
4) What is the
biggest impact
Botox has had on
your life?
5) What has
i) Did you have any
Botox had the
expectations going
least impact on in
into this that you
your life?
were hoping to
have achieved that
were not achieved?
6) What has been i) What are some of
the impact of
the things that you
Botox with regard
would do now that
to participating in
you wouldn’t have
daily activities?
done?
Each interview concluded with the researcher asking the participant if he/she had anything
else to add or mention about his/her experience.
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Interview analysis. Interviews were transcribed verbatim from audio recordings by a
secondary researcher. The interviews were analyzed using the following qualitative guidelines
(Lincoln & Guba, 1985; Tracy, 2010; Finlay, 2002): First, the transcripts alongside the audio
recordings were read and listened to multiple times for familiarity. Once a thorough read was
completed, the transcripts were then uploaded onto online qualitative analysis software, Dedoose
(Dedoose Version 8.0.42, 2017). Next, components of the interviews regarding BoNT-A were
highlighted and organized. Through multiple readings of the interviews, sets of codes were
created based on the content of the interviews (Appendix D). These codes aided in organizing the
content of the transcripts into topic areas. The codes were examined by members of the research
team, through an iterative approach and were revised when necessary to obtain consensus. This
iterative approach promotes the trustworthiness of the data analysis. Next, a final code dictionary
was developed to assign meaningful codes. Lastly, after the interview transcripts were coded and
sorted into their content areas, each of the content areas were examined in detail and themes
were developed to reflect the most significant patterns within and across the coded topic areas.
The final qualitative analysis focused on to:
1)

Identify commonalities and differences among participants’ experiences;

2)

Reflect the complexities and multiple realities among participants through descriptive
accounts;

3)

Illustrate the themes through the language of the participants
(Benner, 1994)
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2.5 Quality Criteria
Quality criteria in qualitative research aim to provide guidelines to aid in trustworthy
research. These are specific criteria and a set of processes that are employed to safeguard the
authenticity of the data. These include: reflexivity, credibility, and multivocality.

Reflexivity. Reflexivity can be defined as thoughtful, conscious self-awareness of the
researchers (Finlay, 2002). Reflexive analysis includes constant evaluation of subjective
responses, inter-subjective dynamics, and the research process itself (Finlay, 2002). Through the
application of reflexivity, a phenomenologist begins their research with the data of their
experience; their own reflecting, intuiting, and thinking and uses that as primary evidence
(Moustakas, 1994). Therefore, reflexive analysis is necessary to examine the impact of the
researcher and participants on each other and the research (Finlay, 2002). Reflexivity
acknowledges the existence of researcher bias and encourages researchers to provide reflective
insights and engage in explicit, self-aware meta-analysis throughout the research process (Finlay,
2002). Reflexivity is seen as an essential component as it improves the quality and validity of
research (Guillemin & Gillam, 2004).
Throughout the research process, reflexive notes were recorded alongside an audit trail (a
form of reflexivity) to aid in the trustworthiness of the data (Appendix E). Audit trails are an
account of all the research decisions and activities throughout the study process, along with
records of the participants’ reactions or emotions and the researcher’s thoughts. Lincoln and
Guba (1985) suggest that by implementing an audit trail, an auditor or second party who
becomes familiar with the qualitative study and its methodology, findings, and conclusions, can
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audit the research decisions and the methodological and analytical processes of the researcher
and confirm its findings.

Credibility. Tracy (2010), defined credibility as the ability to create trustworthiness in
the data presented. This was ensured during the data collection process when the audio
recordings of each interview were transcribed and verified by members of a research team for
any errors or discrepancies. Research assistants who were uninvolved in data collection
conducted the transcription of the data. A secondary researcher reviewed the transcripts and
made notes on where there were discrepancies between what was heard on the recording and
what was contained in the transcript. This has been further implemented through the interview
analysis, which was conducted through an iterative approach amongst the first author, mentor,
and advisory committee. We explored and compared data analysis, and referred to the transcripts
to ensure correct interpretation. Any discrepancies were resolved via consensus of the research
team. This iterative process relates to an approach called crystallization. Crystallization refers to
the practice of using multiple sources, frameworks and methods (Tracy, 2010). Crystallization
will be adhered to via the use of multiple researcher viewpoints. Multiple researcher perspectives
allow for different aspects of problems to be explored, it helps deepen the understanding of the
data, and encourages consistent (re) interpretation (Tracy, 2010). Crystallization accepts that the
goal is not to provide a valid singular truth, but to provide a complex and in-depth, understanding
of the phenomena at hand (Tracy, 2010).
To further ensure credibility, interpretive phenomenology suggests that the “interpretive
team” consists of researchers who are experts in phenomenology or in the content area of inquiry
(Crist & Tanner. 2003). In the analyses of the data, the research team consisted of individuals
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with clinical and research experience treating and working with individuals with dysarthria and
OMD, and research with a background on qualitative research.

Multivocality. Multivocality is implemented in this study to include multiple and varied
voices (Tracy, 2010). The heterogeneous nature of the participants recruited will facilitate an
understanding of experiences from different genders, ages, occupations, and time since disease
onset. As the varied voices of our participants shared their experiences receiving BoNT-A
injections, an authentic understanding of his/her lived experiences was revealed and this created
a space for a variety of opinions (Tracy, 2010).

Chapter 3
3 Results
Two major themes and six sub-themes were developed through the qualitative analysis of
the interview data (Table 3). The first theme, Botox has changed me and my experiences,
explored the participants’ perspective on receiving BoNT-A injections and the psychosocial
impact of receiving these injections. The four sub-themes under this category include: I feel
normal again, I feel appreciative of what Botox does for me, Botox doesn’t fix everything, and
My face looks different. The second theme, What communication is like for me concentrated on
the psychosocial impact and changes to speech production and communicative participation that
participants experienced as a result of receiving BoNT-A injections. The two sub-themes under
this category include: My speech has changed and I can now participate. All themes and subthemes will be further expanded on below, alongside direct quotes from the participants’
interviews to explain the development of each theme.
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Table 3. Themes and Sub-themes
Themes
Botox has changed me and
my experiences

What communication is like
for me

Sub-themes
I feel normal again

Definitions
Personal perspective of
“disability” and the concept of
“normal”

I feel appreciative of what
Botox does for me

Positive emotional reactions,
happiness, increased
confidence, hopefulness,
surprise, improved selfesteem, relief, and impact on
QOL

Botox doesn’t fix everything

Negative emotional reactions,
disappointment, fatigue,
uncertainty, frustration, fear,
and worry

My face looks different

Alterations to facial
appearance/orofacial
aesthetics, self-consciousness

My speech has changed

Speech production i.e.,
response rate, speech
intelligibility, articulation,
and physical effort

I can now participate

Participating in meaningful
activities with family and
friends, changes to
communicative participation

3.1 Theme 1: Botox has changed me and my experiences
Participants expressed how BoNT-A treatment changed their perspective of themselves,
their expectations, and described the psychosocial impact of receiving BoNT-A injections.
Participants also shared their experiences of receiving BoNT-A injections. They discussed how
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receiving their injections resulted in positive emotional reactions, such as happiness, increased
confidence, hopefulness, surprise, improved self-esteem, and relief. However, many participants
also expressed that receiving BoNT-A injections resulted in less positive experiences, such as
disappointment, fatigue, uncertainty, frustration, fear, and worry. Participants also discussed the
psychosocial impact of BoNT-A injections on their facial appearance.

I feel normal again. Participants discussed how they viewed themselves post-injection,
their view of “disability”, and what “normal” means to them. E.P (initials are all fictitious)
discussed how the injections helped him from “slipping into the grey area of disability” (EP, M,
80 years). He expressed his concerns about how he would feel about his self-concept without
receiving BoNT-A injections by stating:
Yes, yes, I need the shots. Or else, I’m in the area of being disabled… I think I would
probably be very limited, definitely. I think the continual eye movement and jaw
movement really make you look as a handicap person, whereas [Botox] has prevented me
from slipping into that area or suffering any of those thoughts or lower self-esteem (EP,
M, 80 years).
Participants also mentioned the idea of feeling “normal” again as a result of the injections. NF
explained that she was going to be “hitting the line of permanent disability” (NF, F, 60 years),
due to her OMD. However, once she received the injections she described a transformation in
her perspective, “It is amazing, it makes me feel normal…I feel like I’ve gone from disabled to
abled” (NF, F, 60 years). NF also stated that post-injection “You can develop a normal life and
just be aware of a few things, you know common sense things” (NF, F, 60 years). JR also
touched on this perception of feeling normal again and how “feeling normal” post-injection
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improved his participation in everyday activities. “You don’t feel as embarrassed of uncontrolled
movements. I’m able to go outside and be as normal as possible” (JR, M, 44 years).

I feel appreciative of what Botox does for me. Participants discussed the beneficial
psychosocial changes they experienced as the result of receiving BoNT-A injections. JR stated:
“It improves the quality of your life. Most definitely”(JR, M, 44 years). BR similarly mentioned
how he found BoNT-A injections helpful, “Yeah it works. It seems to do its job for me” (BR,
M, 68 years). NF discussed that the injections provided her with “inspiration and confidence”
(NF, F, 60 years). She also said it “gives me my life back” (NF, F, 60 years). FI discussed how
the injections had provided her with confidence, “I feel more confident, I think, a bit more
confident because you know, I feel like I try to control [my tongue] when it’s moving a lot. If the
Botox is controlling that movement, that’s an important thing that it’s doing really” (FI, F, 69
years). GM mentioned similar changes with the impact BoNT-A treatment had on his life and
how it improved his outlook:
It has changed my life I think um, maybe not as far as other people can see, but for me I
think it’s changed my life… it gives you, it tends to give you some confidence as well, I
think. Um, dystonia can take some confidence away, but Botox gives it some back. And
um, I think that’s the big thing (GM, M, 69 years).
NF felt as though she was given a second chance when she regained her speech post-injection.
She discussed how the BoNT-A injections gave her the confidence to speak publicly. NF said,
“It was almost like a debt I had to pay right because I’m so thrilled to have [my speech] back”
(NF, F, 60 years). Participants also mentioned their appreciation for the changes that the BoNTA treatment has made. GM stated:
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I know I’ve been asked whether I’ll be taking Botox my whole life. I don’t know if I’ll
have to or not, but um, with age, things change or not…When people ask, you know, I
don’t mind taking that the rest of my life. It’s a godsend …it’s fixed the thing that I
wanted fixed most (GM, M, 69 years).
Participants also expressed their happiness and thankfulness as a result of receiving BoNT-A
injections. NF discussed how “the difference between it is survival. I have a job because of
Botox. I can talk, I can be happy” (NF, F, 60 years). Similarly to NF, ST expressed “Oh, yes I
am happy for any changes, yes, yes” (NF, F, 60 years). EP also shared: “I feel very happy and
fortunate they have something for us. I mean without it I wouldn’t want to face the consequences
without it…I’m very happy about the relief I do get from it” (EP, M, 80 years).

Botox doesn’t fix everything. Despite being appreciative of the benefits of BoNT-A
treatment, all eight participants also acknowledged that BoNT-A injections didn’t fix everything.
Participants described failure of expectations and side effects including pain, muscle atrophy and
bruising. Although GM experienced improvement with the injections, he recognized that Botox
“doesn’t make things perfect, but it does make it as near perfect as it can get” (GM, M, 69 years).
GM further stated:
I wish I wouldn’t still have to have the um, still kind of moving my mouth around. I wish
I didn’t have that. Botox fixes that a bit...And but, it still hasn’t um, gotten my tongue
under control. Umm, I would still have to move it around; I’d still have to manage that
when I didn’t have to manage that before. That might be one thing that it does still leave
you with something (GM, M, 69 years).
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SP discussed how his expectations of the injections were not met. He had been told once
receiving the BoNT-A injections his face would get back to “normal” (SP, M, 78 years), SP
stated: “But that didn’t happen. I guess that was a disappointment, but I guess you could live
with those things, you know?” (SP, M, 78 years). FI who had been receiving BoNT-A injections
for 21 years described her uncertainty of the effect of BoNT-A injections:
I’m not sure now; heaven knows I’m not sure ha-ha…Yeah, um, I think it’s almost a
psychological effect now. You know I’ve come to expect to receive months of Botox and
uh, something will change anyway, whatever it is ha-ha…Doesn’t sound very positive
does that? (FI, F, 69 years).
EP similarly discussed what he wished could be changed: “I wish my muscles didn’t deteriorate
and I would get better and get cured” (EP, M, 80 years). Similarly, ST stated, “I thought it might
help the jaw a little more. But then, it’s only the first time, so I wasn’t expecting miracles” (ST,
F, 78 years).
FI, NF and BR discussed the longevity and variability of symptom relief over the course of the
three-month injection life. FI stated: “Um, yeah I mean I think it’s good for my confidence for
those first few weeks before it starts to drop off” (FI, F, 69 years). NF and BR discussed the
impact of the BoNT-A injection as it wears off. NF stated: “I don’t have as much control when
the Botox is wearing off” (NF, F, 60 years). She discussed what she noticed once the injection
began wearing off.
Umm I notice that the pain and the tension does start coming back. I can tell within 6
weeks of the injection. The tiredness, the fatigue, the muscle is there, the aches, the pain,
the movement, the twitches or you can feel them coming back (NF, F, 60 years).
BR also mentioned:
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When I am on the back side or sort of mid-point of the [Botox], when I start to work up
to having another injection, that’s when it’s worse… I’II start to notice little things and
then it gradually, it gets very, very pronounced (BR, M, 68 years).
Participants also discussed side effects, such as muscle atrophy, bruising, and pain due to
the injections. EP discussed how receiving BoNT-A injections for 22 years affected his muscles.
He stated: “The muscles have deteriorated such that they aren’t normal …even the doctor found
difficulty when giving me the injections too, especially on the jaw muscles; the eye area is very
thin and easy to bruise” (EP, M, 80 years). EP also mentioned how he experienced the injection
cycle and the effect on the muscles pre- and post- BoNT-A injections.
Well, all of sudden you’re going from unable to control the movement of eyes uhh from
closing, your mouth from opening and all of a sudden you’re experiencing the extreme
opposite, I have to first get used to it the 6 or 7 days and then you feel the Botox just
restricting your muscles from the movement that it’s hard to shut your eyes, it’s the
reverse of what’s happening and the same way with your mouth is. It’s hard to open your
jaw muscles it’s so restricted. But umm after a month and depending on the strength of
the Botox you’re never certain how much or how small it is that you’re getting. You’re
loosening up the muscles or at the best of times for at least a month minimum after that
the last month is a slow decline, quite often sometimes not as bad as others. But at the
time during last two weeks, you really need it (EP, M, 80 years).
Pain, as a result of the injections, was a common experience for four of the eight participants.
NF, although she felt as that the treatments were positive overall, mentioned other experiences
post-injection: “There are other symptoms too. I do have problems with the biting of the tongue
once in a while. I have to be careful of that. So I have a few nodules from biting the tongue too
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hard” (NF, F, 60 years). BR also discussed that “sometimes I’ll bite the inside of my mouth or
heaven forbid I bite my tongue and then it sends you right off to the ceiling” (BR, M, 68 years).
He goes further to describe more uncomfortable side effects such as “dry mouth especially at
night, that’s a problem” (BR, M, 68 years). He stated:
I get up in the morning and sometimes this lower lip is stuck to my teeth. And if you
wake up and you don’t recognize that effect, you pull your lip away, you know, just
getting up and you open your mouth, that creates a lot of little sort of micro tears in the
back of the lip; and then the first thing you know, the thing is swelling and it’s very sore
(BR, M, 68 years).
NF also mentioned the pain associated as a result of receiving the injections and the challenge of
correct dosing. She explained:
Oh the injection hurts for about 30 seconds, it swells, you have to be careful umm each
day it does create more swelling so you have to be more aware, you have to physically be
aware of what you’re doing and how much swelling you do have…And being in the
tongue you know what are going to be the side effects of that injection, am I going to be
back in emergency in 24 hours from now or three days from now with a swollen tongue
and not being able to breath (NF, F, 60 years).
SP similarly discussed the pain of the actual injection, the trauma to the muscle and how long it
took to heal.
It really was quite sore… I had 25 needles. That’s sore for a while. Any muscle if it’s
damaged is going to be. It’s not going to act normal for a while … It take 2 weeks
sometimes it would be a little bit longer, till the healing. Till the muscles healed from the
injury, from the trauma (SP, M, 78 years).
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SP and JR mentioned their experience of tightness after the injections: SP stated: “Because the
Botox releases the muscles. The tightness. There’s more tightness there, especially like I said
after the injections, but there’s still some tightness” (SP, M, 78 years). JR also stated: “Just tight,
but it wasn’t pain…it still becomes tight when I try to talk (JR, M, 44 years).

My face looks different. Participants described changes related to orofacial aesthetics as
a result of receiving injections. They discussed their perceptions of how BoNT-A injections
affected their facial appearance, how the injections have impacted the function of their muscles,
the trauma resulting from the injections in the form of redness, their level of self-consciousness,
and how other people have reacted to their facial appearance.
Participants discussed their perception of positive changes to their facial appearance postinjection. FI discussed that she was less worried about dystonic facial twitches, especially when
she was in social situations, during the first couple months after her injections.
When I, the first half anyway [referring to the first half of the injection cycle], I don’t
seem to have to worry as much about, you know, if I’m going into a social situation
especially if I’m going to be sitting there twitching all the time or am I going to be
reasonably personable (FI, F, 69 years).
Similarly, JR discussed how he felt the injections changed his facial appearance and how he is
less concerned about dystonic movements in his face. He stated, “I don’t feel like I’m worried
about my face being moved so much…It’s calmed my face down a bit” (JR, M, 44 years). NF
and SP also reported positive changes to their facial appearance post-injection. NF stated,
“There’s your whole appearance issue” (NF, F, 60 years). When asked what Botox had the most
impact on, SP stated “facial appearance” (SP, M, 78 years). ST mentioned that prior to her
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injections “the kids noticed” changes in her appearance and had said “Mom, you got to do
something!” (ST, F, 78 years). She described what her face looked like prior to receiving BoNTA injections and the resultant changes post-injection. She stated:
My mouth was drawn down. It almost like… have you seen Bell’s palsy? Yeah. Almost
like that. Only it wasn’t Bell’s palsy. But that all cleared up [post-injection] because the
muscles were relaxed and they could find a way to bring all the facial features back to
where they were supposed to be (ST, F, 78 years).
BoNT-A injections did not improve facial aesthetics for all participants. Participants described
some perceived negative effects on their facial appearance, or they perceived no noticeable
change following injections. GM discussed that post-injection he needed to use his tongue to
clear food from sticking to his teeth and he described how he thought this affected his
appearance. He stated, “that’s an appearance thing, so you don’t want to be sticking your tongue
out of your mouth” (GM, M, 69 years). GM also discussed how the injections made him selfconscious of his appearance. He explained that as a result of the injections he has a “grimacing”
expression, yet the benefit of Botox “outweighs anything it does to appearance” (GM, M, 69
years). He stated:
It does something to my appearance with that…Well I think that the marks here, and you
know…it only happened about 6 months ago when me and my wife started to see
[Dr.xxx] And so he said we have to adjust [the injections] on the other side. Right now
when you… it’s kind of hard... it pulls one way so we have to pull it back the other way.
Yeah, so um...I think the Botox, has an effect on appearance…. Almost every 3 months
we’ve probably adjusted a little bit. Because I know in the last 6 months they adjusted it.
The... my corners of my mouth were falling down I was almost like well, a grimacing
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type thing. So we have to counteract that by putting more Botox on the other side so it
kind of pulls it up. You can kind of see the red marks in the corner of the mouth up
there…I noticed right away, and I think everybody else notices right away. Umm so we
kind of do that but I don’t want to, like, I said, I didn’t want to look like the Joker after
(laughs) (GM, M, 69 years).
FI stated that although she is uncertain of how Botox is specifically helping her dystonia, she
continues to take the injections for cosmetic reasons.
My mouth was continually moving. So [Dr.xxx] used to try and inject around my mouth,
so that would be lessened. Um, but I’m not really sure that that did help.. I mean it has
made me feel that the movement is diminished. I know I’ve noticed that lately I am
getting about half of what I used to get fifteen, twenty years ago…we’re almost working
towards trying to lessen the motion so that they’re not moving, you know… in almost
distorted ways…So, uh I mean it’s becoming almost a cosmetic, I mean I guess it always
was a bit of a cosmetic thing, I have to admit that (FI, F, 69 years).

3.2 Theme 2: What communication is like for me
Participants described changes to their speech production and communicative participation as
a result of receiving BoNT-A injections and the psychosocial impact associated with receiving
the injections. Results were varied, with some participants experiencing noticeable
improvements in their speech production, while other participants experienced little to no change
in their speech production post-injection. Participants also discussed how BoNT-A injections
impacted their communicative participation and psychosocial functioning.
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My speech has changed. All participants described changes to their speech production as
a result of receiving BoNT-A injections. Participants discussed changes to their speech
intelligibility, articulation, response rate, and amount of physical effort required to speak.
Participants compared and contrasted their speech production before and after receiving
BoNT-A injections.
BR, FI, and EP discussed how their speech intelligibility had improved post-injection, but
they also described when their speech production was most improved over the course of the
injection cycle. BR stated:
Oh my speech was terribly slurred…I think the clarity and the understandability sort of
show up when I’m in this position right now. Like this far from having another shot (6
weeks post-injection). I think [Botox] loosens up these muscles in my face and allows
me to pronounce words easier, so I don’t have this sort of slurring, if you will (BR, M, 68
years).
Similarly, FI mentioned: “I have to think about the speech thing whether it does help. Uh, I
think it does help initially when I have it, for the first you know, few weeks anyways and then
there’s the, you know, wearing off process” (FI, F, 69 years). EP also stated: “You’re much more
restricted with formulation of words, and the length of time it takes you to get it out, when you
receive the Botox. After Botox is in for a month or so, your speech progressively gets better”
(EP, M, 80 years). SP also described that although the injections worked to improve his speech
production, it took time for his speech production to be optimized.
I had problems enunciating words. I couldn’t enunciate them clearly, uh, and maybe
people thought maybe I got marbles in my mouth and wouldn’t speak very clearly. And
that started to improve after I’ll say, for a year. And um, after that, I felt really good about
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it because after the first week, or maybe like two weeks I felt like I could speak clearly
(SP, M, 78 years).
Participants explained how their articulation improved post-injection, and they also described
their reactions to changes in their speech production. For example, NF discussed how Botox
provided her with the ability to regain her speech and how it improved her articulation.
I can’t say enough about the use of Botox. I mean I can remember, I can speak...hello,
you know…I don’t think you can imagine going from “wah wah wah” and then 10
seconds after that injection to be able to say something, a word. I’m just flabbergasted. So
it’s super extreme as far as nothing to 100 percent. I couldn’t say a word, it’s just
phenomenal to me (NF, F, 60 years).
NF continued: “Umm I think my speech is pretty good. Most people don’t notice that I ever had
a speech problem…I can say t’s better, sh’s better, but I don’t always hit them” (NF, F, 60
years). SP also explained how his speech production improved post-injection. He stated, “The
Botox relaxes some muscles, and it’s easier for me to form the letters…I have less trouble
speaking” (SP, M, 78 years).
Although SP described improvements in his speech, he also described some difficulties
that arose post-injections. He stated:
I found that it’s either the trauma of the needles in the face, or the Botox itself that would
uh, cause me to um, speak… I have a problem with speaking and particularly enunciating
because the lips didn’t seem to want to make the sounds, you know? You want them to
make like o’s and a’s and you know, r’s... or particularly anything that would have… “o”
with an “o” in it… and lips, and even as I’m speaking to you right now. Anything with an
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“o” in it, the lips don’t seem to one to come together enough to clearly enunciate that “o”
(SP, M, 78 years).
Participants explained how the injections increased their ability to respond when
speaking. GM discussed how his response rate was “A lot quicker.” He stated:
Well, it has definitely helped me. Umm, see, my tongue and my brain. It seems to be a lot
more in sync. Before I took Botox we probably could have measured the time it took
after you had asked the question for me to start replying… there is a wire between my
brain and my tongue that before was broken. Now it’s fixed that wire (GM, M, 69 years)
SP also mentioned how the injections helped him. He stated:
“You’re not thinking of, how should I answer that question, what words should I use, it’s
sort of like an automatic situation. So when I get [Botox], it’s like putting your speech on
autopilot. It just seems to work…it makes me think quicker. You think oh, ok” (SP, M,
78).
Participants discussed the amount of physical effort they exerted when speaking. GM discussed
how the injections had helped him decrease the amount of physical effort he required to speak.
He stated:
I don’t have to work so hard on the speech things. It’s helped because I always felt I had
to work on certain things to make it always the best or the better, but without Botox, I
would have a hard time I think doing that (GM, M, 69years).
BR mentioned that post-injection he was able to put in less effort. He explained:
It helps your speech for sort of a month and a half or two months. Then after that, it’s a
little more difficult. So you’re not conscious of making an effort. You’re not conscious of

43
your speech being slurred. So I think that’s the biggest thing it has done for me (BR, M,
68 years)
SP also discussed physical effort, but his experience was in contrast to GM and BR. SP stated
that after receiving the injections, he needed to “put a special effort into [speaking] ” (SP, M,
78). He further explained, “I have to put just a little more effort to making, enunciating certain
sounds…I found that it’s either the trauma of the needles in the face, or the Botox itself that
would uh, cause me to um, speak” (SP, M, 78 years).
Not all participants described a positive change to their speech production post-injection.
Some participants discussed their uncertainty about any noticeable changes to their speech
production, with some participants stating that they experienced no change to their speech
production post-injection, as well as one who previously noted some positive changes. JR
explained, “Oh. No, no. My speech. I feel. No, it hasn’t increased; it hasn’t done my speech at
all… It’s about the same. It hasn’t gotten worse. It hasn’t gotten better” (JR, M, 44 years). ST
also discussed her uncertainty when asked if there were changes she had noticed. She said, “Uh,
not a whole lot, speech, maybe” (ST, F, 78 years). Similarly, when GM was asked about speech
intelligibility and any changes that were experienced in his speech he responded, “um, I don’t…I
don’t know…I don’t think so” (GM, M, 69 years).
Although EP mentioned improvements in his speech, he also discussed some speech
problems he wished BoNT-A injections had helped with. He stated: “Umm, I wish I had less
speech problems. I know I’m limited in speech slowness and pronunciation but you just have to
accept it and move on” (EP, M, 80 years).
EP who had been receiving BoNT-A injections for 22 years explained that his speech production
had changed over the years. He attributed this change to be the result of the deterioration of his
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facial muscles due to his long history of receiving BoNT-A injections to manage his OMD. As a
result of muscle atrophy, EP mentioned that he received the injections less frequently. He stated:
For the last year or so I find that even at the end of [the injection cycle] now because of
the deterioration of the muscles, that period before I get the shots I’m still having trouble,
slight limitations than what it used to be. I used to probably speak better before, but it’s
getting progressively worse so umm I can’t get [the injection] every 3 months, for the jaw
anyway (EP, M, 80 years).
EP also described changes to his speech intelligibility and speech rate as a result of receiving the
injections for 22 years EP stated, “umm speech became thicker and changed, slower, took more
time to formulate the jaw, tongue, throat muscles to make pronunciations that would normally
just roll of your lips prior to that” (EP, M, 80 years).

I can now participate. Participants described their ability to participate in meaningful
activities with their families and friends and how the ability to participate affected their
psychosocial functioning. Participants also explained how changes to their speech production
post-injection affected their communicative participation, including their ability to have
meaningful conversations, communicate in social, public, and private settings and their ability to
express their emotions and opinions accurately through their speech.
Participants discussed the meaning of communication and communicative participation
and the importance of these in their lives. GM discussed that his “communication ability is a lot
better”(GM, M, 69 years), as a result of receiving injections. He explained that the injections had
made it easier to talk and increased his confidence to communicate with others. He stated:
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I think the big thing is that um, I’m not totally afraid to talk. So if I didn’t have the
Botox, I would feel very hampered about talking. Uh, but either one-on-one or in a group
or anything. I feel um, maybe more confident about that. I think I would always kind of
keep trying harder to do something, but this makes it a lot easier. If they’re going to ban
Botox, I would be very, very afraid (GM, M, 69 years).
NF explained how the ability to communicate changed her life. She stated:
My speech, gave me my job back. Gave me my husband’s conversations back,
relationships, children and family and work. Isn’t that life? That’s everything. And you
know now I’m able to give back, and I wouldn’t be able to before. I feel like I’m
contributing to the community (NF, F, 60 years),
NF further discussed the importance of communication and how the injections improved the
important relationships in her life, her employment, and her well-being. She stated:
I have a job because of Botox. I can talk, I can be happy. I can laugh and communicate all
of that emotionally, socially everything. It makes a difference between living and really
not. You’re just surviving. When you’re not speaking and you don’t have that
communication, you’re surviving. You’re self-fulfilling and you can find other ways to
study or read and educate yourself but you’re not sharing. It’s not a sharing thing. It’s a
very personal, inward type of existence whereas with speech; the difference is night and
day. You can communicate, you can share. People can make you laugh you can make
them laugh just through speech. You know, you can have a job and you cannot have a job
(NF,F, 60 years).
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NF also stated:
Well, considering I like to work, umm that’s a big impact because then I’ll be going back
to doing what I like the most in my daily life, I like working umm so that is to me the
biggest, and communication with family are the two tops in my book as far as my life.
And my life would totally change without it (NF, F, 60 years).
NF and SP both discussed how other people viewed their ability to participate and communicate
post-injection. NF mentioned her experience participating in her job post-injection and how
people viewed her ability to communicate. She stated:
I think it’s affected in so many ways when I went back to work, I became more confident.
I became like a mentor kind of. Some of the people and my acquaintances that I knew
were so surprised even I think the occupational health and safety person were shocked
literally that I was ever able to come back to work from seeing me before I went and then
coming back. Matter of fact, I ran into her a week ago and she said “I still can’t believe
that you were on the disabled road forever and then you’re here now many years later”
and um she can’t believe the difference of my speech like speaking normal. So I know
that there’s a vast difference there. I had a friend an acquaintance at work who marvelled
at how positive (NF, F, 60 years).
SP also mentioned how others viewed his communication skills post-injections. He stated:
Very few people ever asked me to repeat anything - either on the phone or in
conversation with uh, an acquaintance or even strangers. The fact is, I had people tell me
after about a year, maybe in the second year I think, said “You’re speaking well… we
never knew you… we never knew you were any different than what you are right now
(SP, M, 78 years).
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Similar to NF, SP discussed how his communication had changed post-injection and the meaning
he attributed to these changes by stating: “I find it easier to speak and to communicate in a way I
want to communicate it. That’s a big difference to me. And important to me” (SP, M, 78 years).
SP elaborated:
Well number one, you don’t have to repeat. Number two, you can get your message
across. Number three, they can understand it the way you want it communicated. You
know I think that… a big thing in communication is, you can say something or write
something, but does the hearer, does the reader interpret it the way you want to say...
“Well, what do you mean here?” “Well I meant this.” “Well, I’m sorry that’s not what it
says.” You know, but it’s... there’s a big skill I think in communicating that everybody
can hear you… what you want to say, how you want to say it, and you know, and it’s got
the meaning and emotion behind it the way you intended it to be said….being able to,
you know, communicate. That people can hear what I want to say, not only the words,
but the meaning to the words. I think are important. And that’s important to me. And I
said, “Well I didn’t mean it that way, I wasn’t upset.” “How come you’re such an old
grouch”?! (SP, M, 78 years).
SP further discussed the importance of regaining effective communication post-injection, and he
also described the challenges he faced when he could not communicate effectively. He stated:
Communication is… a two-way communication is easier, because you know, it’s difficult
to have good communication, and good relations you know, if one person is saying
something, and I don’t know what he’s saying, I have to guess at what he’s saying; I have
to guess at what he means. It’s difficult for the other person, but to answer your question
specifically, you know. That two-way communication is easier, more relaxed, and less
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stressful, and I’m saying the same thing maybe, but you know, if you get that good
communication with somebody else, and the most natural situation, you know, it’s just,
the other person’s more fun to be around, and you’re more fun to be around the other
person, right? But if you a have serious impediment, it’s difficult for two reasons: they
don’t understand you and they get frustrated, and they’ll feel a certain amount of sorry for
you, like you can’t communicate any better than what you’re doing. I know I always feel
that way if someone has a problem that you feel, you feel that you can’t communicate
with that person so well, but you feel sorry for him that he’s… that he or she is in that
situation (SP, M, 78 years).
Similarly, NF explained the importance of communication and how it impacts the ability to
express one’s needs. NF stated, “Communication is a big…I mean with any diagnosis you have
to have communication, you go to any doctor and you have to be able to say what’s wrong with
you”(NF, F, 60 years).
Although JR discussed that his speech stayed “about the same” post-Botox injections, he
still felt that the injections had allowed him to become “more social.” He stated: “Because I’m
not making it affect my job, work-wise, I can be more social” (JR, M, 44 years). Similarly, EP
stated, “I find the Botox gives me ability to sit through a movie or just have a conversation with
some people, whereas I would be severely restricted” (EP, M, 80 years). ST also described,
“Well, I don’t hesitate to be out and be talking as much as I was before… it improved my daily
activities by going out with people” (ST, F, 78 years).
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Chapter 4
4 Discussion
The purpose of this study was to obtain a self-reported account of the psychosocial
consequences of BoNT-A injections for individuals living with OMD. Using qualitative
phenomenological methodology, this study explored how participants judged the success of
BoNT-A treatment based on the psychosocial issues relevant to them. This was achieved by
understanding the insider’s perspective through an interview process, where participants
discussed and shared their treatment experiences. The discussion will further explore the results
of the study and compare it to previous literature and research that has explored similar concepts.
This section will also outline the study limitations, clinical implications, and future research
directions.

4.1 Perspective and Experience
Two major themes emerged from this research. The first theme, Botox has changed me
and my experiences explored the participants’ perspective on receiving BoNT-A injections and
the psychosocial impact of receiving these injections. From this first theme, four subthemes
emerged. In first subtheme, I feel normal again, participants discussed that prior to receiving
BoNT-A injections they felt disabled by OMD, but following injections many participants
reported feeling less disabled and a return to a pre-disability sense of “normal”. A study by
Baylor, Yorkston, Eadie, and Maronian (2007), examined the psychosocial consequences of
Botox treatment for SD, and reported similar findings to our research. Baylor and colleagues
(2007) found that post-BoNT injections participants experienced a relief of SD symptoms,
allowing them to feel and act like themselves again. The concept of return to pre-disability
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“normal” was examined in a study by Novakovic, Waters, Elia, and Blitzer (2011). Novakovic
and colleagues examined the longitudinal effects of BoNT treatment in participants with
Adductor Spasmodic Dysphonia (ADSD) on functional outcomes and QoL. Patients completed
an evaluation of their voice function after each injection using the percentage of normal function
(PNF) scale and the Voice Handicap Index (VHI; Jacobson, Johnson, Grywalski, Silbergleit,
Jacobson, Benninger, & Newman, 1997). These results showed that post-injections the average
score on the VHI increased by 9.6% and the average PNF score increased by 30.3%.
Participants also discussed the beneficial psychosocial changes they experienced as the
result of receiving BoNT-A injections, as captured in the second subtheme, I feel appreciative of
what Botox does for me. Participants spoke about the perceived improvement in their QoL,
increased confidence, and improved happiness post-injection. More specifically, our participants
discussed that they experienced increased confidence in their ability to regain control of their
orofacial movements and discussed the concept of a ‘second chance’. In this sub-theme,
participants also discussed improvements in aspects of OMD they wanted improved following
injections such as the ability to communicate more effectively. Finally, participants described
how receiving BoNT injections improved their overall happiness.
Our participants’ appraisal of improved QoL as a result of receiving BoNT-A injections
is similar to the findings reported by Charous and Comella (2011). This study examined QoL
following Botox injections for individuals with jaw-opening dystonia and reported improvements
in QoL for all participants post-injection. Their participants reported feeling more optimistic, less
embarrassed, and generally felt better about themselves as a result of the injections (Charous &
Comella, 2011). Our results are also consistent with the findings of Natasi et al. (2016) who
examined the effect of BoNT-A injections on QoL in participants with isolated lingual dystonia
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and OMD affecting the tongue. The results of this study revealed that following BoNT-A
injections, participants reported a positive change in QoL as measured by a disease-specific
questionnaire, the oromandibular dystonia questionnaire-25 (OMDQ-25; Merz et al., 2010). All
domains of the OMDQ-25 showed improvement post-injection. Bhattacharyya & Tarsy (2001)
also found that participants reported less depression and anxiety related to SD and/or OMD, and
improvements in QoL post-BoNT treatment. The GBI was used as a measurement tool, to
quantify the health benefit of BoNT injections. The general sub-score, social support sub-score,
and physical health sub-score, all demonstrated statistically significant increases, showing that
patients benefited from the injections (Bhattacharyya & Tarsy 2001). A study by Hogikyan,
Wodchis, Spak and Kileny (2001), explored the longitudinal effects of BoNT injections on
voice-related quality of life using the V-RQOL scale (V-RQOL; Hogikyan & Sethuraman, 1999)
in 18 patients with ADSD. The results of the study by Hogikyan and colleagues (2001)
demonstrated an improvement in V-RQOL, following BoNT injections. Another study by
Courey, Garrett, Portell, Billante, Smith, Stone, and Netterville, (2000), studied 38 participants
with SD receiving BoNT treatment and found similar improvements in QoL using the Voice
Handicap Index scale (VHI; Jacobson et al., 1997) and the Short Form-36 scale (SF-36; Ware,
Kosinski & Gandek, 1993), a 36 item patient-reported outcome that measures patient health,
related to quality of life. Each outcome measure (i.e., VHI, SF-36) was administered to
participants before treatment and one month after treatment. Following BoNT injections,
participants reported a significant improvement in scores on both the VHI and SF-36. There were
improvements in the participants overall VHI scores, and improvements in their functional,
physical, and emotional handicap category scores post-treatment. On the SF-36, patients showed
significant improvements in their mental health and social functioning scores.
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Finally, a study by Faham, Torabinezhad, Murry, Dabirmoghaddam, Abolghasemi,
Kamali, and Asgari, (2018) evaluated QoL and voice changes over multiple time points in 15
participants with ADSD. Participants completed the Voice Activity and Participation Profile –
Persian edition (VAPPP) (Ma & Yiu, 2001) pre-injection, and at 1, 3, and 6 months postinjection. The results of the Faham et al., study demonstrated that participants reported the
greatest gains in QoL (as measured by the VAPPP) at 3 months post-injection, despite voice
quality not being judged as normal. This finding of improved QoL, despite remaining voice
impairment, relates to the third subtheme, Botox doesn’t fix everything, which is discussed next.
Although the participants in this study expressed some positive psychosocial benefits of
BoNT-A injections, all eight participants also acknowledged that BoNT-A injections did not fix
everything. Participants described failure of expectations and side effects as a result of the
injections. Participants discussed unpleasant side effects, such as muscle atrophy, bruising, and
pain due to the injections. EP discussed how receiving BoNT-A injections for 22 years affected
his muscles, causing deterioration and pain. A study by Baylor et al., (2007), examined the
psychosocial consequences of Botox treatment for SD. The six participants with SD in the
Baylor et al. study described the burden of Botox treatment, such as the fear and pain of
receiving the injections, the cyclic and sometimes-inconsistent voice response, and the need for
repeated injections. Our participants described dissatisfaction with the cyclic and changing
nature of response, over the course of their BoNT-A injection cycle, with respect to speech
production (expanded on in the next theme), as well as physical and emotional impacts.
Participants in our study reported that their confidence decreased as the BoNT-A injections wore
off, as well as loss of control, pain, tension, and fatigue, which developed towards the end of the
injection cycle. Dry mouth is another reported side effect of Botox injections (Goldman &
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Comella, 2003; Gn & Ng, 2017). Dry mouth was described in our research as an unwanted side
effect. One participant, BR described the pain associated with dry mouth post-injection, causing
his lower lip to stick to his teeth resulting in tears and swelling.
Failure of expectations regarding the effectiveness of BoNT-A injections in providing
relief from a number of OMD-related symptoms was also reported in our study. Participants (SP,
GM, FI, SP, and ST) discussed what they had wished BoNT-A injections could have helped or
changed. Participants discussed that they wished they could regain control of the continuous
orofacial movements, their face would go back to ‘normal’ post-injection, that their muscles
would not deteriorate, and that after treatment they would get better and be cured. Baylor et al.,
(2007) reported similar findings, in regards to the participants’ ‘ideal’ Botox injection.
Participants discussed that they wished that the injections were quick and pain-free, that there
would be no breathy periods, the injections would last longer, they would have the ability to say
sentences correctly, speak without thinking, or feel self-conscious (Baylor et al., 2007). The
results of our study support the findings of other studies, demonstrating that BoNT-A injections
do not fully meet expectations for every participant and this treatment can be associated with
dissatisfaction and unwanted side effects.
Finally, in the fourth subtheme, My face looks different participants described changes
related to orofacial aesthetics as a result of receiving BoNT-A injections. Many participants
discussed experiencing positive changes to their facial appearance post-injection. These
participants explained that they felt less self-conscious and less worried about unwanted dystonic
movements, such as facial twitches, following injections. In addition, some participants (FI and
SP) stated that the most important aspect of receiving Botox injections, were the positive
changes to their facial appearance. This finding is consistent with that of Merz and colleagues
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who explored and highlighted the importance of facial aesthetics in the participants they studied
with OMD. In this study, Merz et al., (2010), evaluated the health-related QoL of 30 participants
with OMD using a disease-specific measure, the OMDQ-25, at pre-treatment and then at four
and eight weeks after BoNT-A treatment. The results of the Merz study revealed that the
cosmetic sub-score of the OMDQ-25 demonstrated the greatest positive difference between preand post-BoNT-A injections. In our study not all participants experienced positive changes to
their facial appearance following BoNT-A injections. Some participants reported feeling selfconscious as a result of the injections. GM described having red marks on his face as the result of
the needles, and experienced grimacing as a side effect of the injections. Taken together, these
findings indicate that individuals with OMD are highly sensitive to their outer appearance (Merz
et al., 2010).

4.2 Speech Production and Participation
The second theme, What communication is like for me explored the psychosocial impact
related to participants’ speech production and communicative participation as a result of
receiving BoNT-A injections. Captured in the first subtheme, My speech has changed
participants reported changes in their voice and changes in the effort to speak as a result of
receiving BoNT-A injections. Participants discussed changes to their speech intelligibility,
articulation, response rate, and amount of physical effort required to speak. Many of our
participants described an improvement to their speech intelligibility and speech production.
Dykstra et al., (2007a) explored the effect of BoNT-A on speech intelligibility in an individual
with lingual dystonia and reported positive changes to speech production, with a 12.4% increase
in single word intelligibility and a 2.7% increase in sentence intelligibility following BoNT-A
injections. Participants with SD in the Baylor et al., (2007) study reported a sense of ‘freedom’
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from not having to worry about their voice post-injection. Baylor and colleagues also found that
all participants experienced improved voice quality following Botox injections, with some
participants reporting that their voices ‘essentially returned to normal’ when Botox was at its
peak effectiveness. Despite some of our participants reporting improved speech production as a
result of BoNT-A injection, other participants’ perceived minimal or even no changes to their
speech production post-injection. This finding is similar to that of Dykstra et al., (2015), who
reported that 7/10 participants with OMD and dysarthria did not show significant improvements
in speech intelligibility over the course of a BoNT-A injection cycle. Our participants (BR, FI,
EP and SP) also reported dissatisfaction with the cyclic and inconsistent changes to their speech
production over the course of their injection cycle. FI mentioned that the injections helped her
speech initially, only during the first few weeks. Our findings are consistent with a study by
Paniello, Barlow and Serna (2008) administered the V-RQOL to 22 participants with ADSD
every four weeks over the course of their BoNT-A injections cycles in order to “to quantify the
proportion of each cycle during which patients experience meaningful benefit” (Paniello et al.,
2008). The results of this study reported that significant voice benefit was derived for only 30%
of the injection cycle. Baylor et al., (2007), found that their participants reported that the cyclic
and inconsistent voice response after Botox was a burden. Our results suggest that the benefits of
BoNT-A on speech production are variable not only over the course of the injection cycle, but
across our participants.
Many participants in our study also described that they required less effort to speak postBoNT-A injection. Baylor et al., (2007) reported a similar finding in their participants with SD.
This study reported that their participants ‘sought relief from physical symptoms of effort and
fatigue as a result of getting the injections’. However, not all of our participants experienced
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reduced effort when speaking. For example, SP stated that, “I have to put just a little more effort
to making, enunciating certain sounds”. Baylor et al., (2007), also reported similar results in their
participants with SD. More specifically, immediately after the injection, participants felt that
their voice was at its weakest and that towards the end of the injection cycle, the amount of
physical effort to speak would return.
Another finding of this study related to changes in communicative participation following
BoNT-A injections. This finding is captured in the second subtheme, I can now participate. Our
results align with the results reported by Dykstra et al., (2007a) who found a positive difference
in all participation restriction scores (and activity limitation scores) on the VAPP following
BoNT-A injections. Importantly, the participant in the Dykstra et al., (2007a) study reported no
activity limitations and participation restrictions relating to her job and social communication as
a result of receiving BoNT-A injections. Baylor et al., (2007) also discussed that their
participants with SD were able to experience new opportunities post-injection, and reported
improved participation in social and community activities following injections. Other studies
have reported that participants rated themselves as more ‘social’ post-injection (Charous &
Comella, 2011), reported improvements in daily communication (Faham et al., 2010), and
reported a reduction in social isolation and public avoidance (Epstein, Stygall & Newman, 1997).
Similarly, participants (JR, EP, ST, SP, NF and GM) in our study reported the importance and
meaningfulness of participating in social activities with family and friends, and that participation
was improved post-injection. ST reported that post-injection, she felt an improvement in her
daily activities. More specifically, she described that she no longer hesitated to go out and talk
with people. The results reported in Baylor et al., (2007), also discussed how Botox injections
helped their participants with SD return to activities that they valued and to resume a ‘sense of a
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normal life’, without their voice ‘controlling’ their participation in activities. The results
presented by Baylor et al., (2007) align with the results of the current study by demonstrating
that participants with OMD and SD report improvements to in social engagement and
community participation post-injection. Our participants also reported how they were able to
return to work following BoNT-A injections. Participants (NF and JR) reported that BoNT-A
treatment allowed them to return to work and resume meaningful occupation. Similar to our
findings, a study by Meyer, Hu & Hillel (2013), examined employment for individuals with SD
who were receiving BoNT-A injections. A total of 145 patients with SD completed the Work
Productivity and Activity Impairment (WPAI; Reilly, Zbrozek & Dukes, 1993) instrument, the
Voice Handicap Index-10 (VHI-10; Rosen, Lee, Osborne & Murry, 2004) and underwent a
perceptual evaluation (Consensus Auditory-Perceptual Evaluation of Voice) (CAPE-V;
Kempster, Gerratt, Verdolini Abbott, Barkmeier-Kraemer & Hillman, 2009) in order to compare
work outcomes with patient-perceived voice handicap and clinician-perceived voice quality. The
results revealed that patients with SD reported that their vocal dysfunction caused a significant
negative effect on work productivity and increased their activity limitations, which improved
post-injection (Meyer et al., 2013). Across all of the studies, including the present study, it
appears that communicative participation is identified as important and is improved as a result of
BoNT-A injections.

4.3 Limitations of the Current Study
In this study, qualitative methods were employed to obtain the experience of living with
OMD and receiving BoNT-A treatment from a psychosocial perspective. Phenomenology was
used in this study because it allowed complex data to be collected through a self-reported
account of participants lived experiences. Although this methodology has advantages, there are
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also limitations. Data collection, analysis, and interpretation is substantial. Due to the time
constraints of a student project and difficulties with participant recruitment resulting from the
rare nature of OMD, our study was completed with a sample size of eight participants, despite an
original target of 10-12 participants. While common themes emerged with our eight participants
studied, a larger sample size would improve the rigor of the data, in terms of multivocality and
saturation. A larger sample size would have also allowed for an increase in varied responses
from individuals with OMD and their lived experiences of receiving BoNT-A therapy.
Furthermore, all participants in this study were recruited from the Movement Disorders Clinic,
London Health Sciences Centre in London, Ontario, which may have also led to a uniform
demographic.
Member checking or respondent validation is a criterion put in place to improve the rigor
of qualitative research to ensure validity and credibility. Member checking is accomplished by
having participants validate their responses from the research interviews. It asks that participants
verify the themes once the researcher has analyzed the data. (Lincoln & Guba, 1985). This
process ensures that the results are in fact capturing what the participant was aiming to say. A
component of this practice was completed during the interview process, whereby the researcher
clarified participants’ responses for correct interpretation and meaning during the actual
interview. Unfortunately, the complete implementation of respondent validation was not
completed within the time frame of this paper, however, our participants will be contacted in the
future to obtain this information.

4.4 Future Directions
The results of this study provide a platform for additional research that examines the
psychosocial impact of BoNT-A treatment for the management of OMD. A future study may
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wish to employ alternate qualitative methodologies, such as grounded theory (Glaser & Strauss,
1967) in order to provide a generalized theory on the psychosocial impact of receiving BoNT-A
injections for patients with OMD. This theory seeks to explain the phenomenon at hand and can
be used as a predictor to explain future experiences of the phenomenon (Mills, Bonner &
Francis, 2006). This research methodology could allow for the collection of additional data from
the participants (i.e., personal diaries), incorporate pre-existing literature and include
observations that the researcher has made throughout their interactions with the participants
(Mills et al., 2006). This data could provide a broader and deeper understanding of the
psychosocial impact of BoNT-A injections in the OMD patient population.
A study consisting of a larger sample size could be collected and compared to the
findings in this study to test for theme saturation, or if there are new findings that could be
discovered. In addition, a future study may wish to re-interview the same participants with a
follow-up study at a five or ten year period to determine and compare if the same issues still
present as relevant or if perspectives of treatment have changed or evolved over time. A study
comparing traditional objective measures of treatment success could be compared to subjective
measures of treatment success in order to determine if the traditional objective measures are
capturing the relevant and meaningful outcomes that are important to the individual living with
OMD.

4.5 Clinical Implications
The results of this study provide information about the psychosocial consequences of
BoNT-A treatment for OMD that can help inform clinical practice. Understanding the
participants’ perspective on treatment can help improve rehabilitation in this clinical population.
The results of this study highlighted the positive and negative consequences of BoNT-A
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injections relating to QoL, speech production, and participation from the perspective of the
participant. From these results, we were able to distil the following conclusions that have clinical
applicability and importance when working with this clinical population.
The first is that BoNT-A injections generally result in positive outcomes and
psychosocial consequences, however, chemodenervation should not be viewed as singular or one
that addresses all concerns or issues. This is an important clinical issue because
chemodenervation via BoNT-A injections is the primary therapeutic treatment for patients with
OMD (Teemul et al., 2016) and is considered to be the ‘gold standard’ and the most effective
treatment for OMD (Kazerooni & Broadhead, 2015). We advocate that adjunctive therapy, in
addition to chemodenervation, should always be considered in order to provide broader and more
holistic care for this patient population. This could include counselling, occupational therapy,
dentistry, and speech therapy, as examples. Although our participants reported that BoNT-A
injections resulted in variable speech production and facial appearance outcomes, these factors
were reported as a priority and important for our participants in judging the success of their
treatment. Therefore, it is prudent for clinicians to provide additional management such as the
provision of a bite block that could improve not only facial appearance, but also articulatory
precision, and hyperactive movements associated with hyperkinetic dysarthria (Dworkin, 1996;
Goldman & Comella, 2003). Additionally, communicative interaction strategies, such as dyadic
strategies to improve communication or modifying the communicative environment to improve
visual and auditory acuity, may be appropriate to ensure successful communicative participation
(Duffy, 2013). Further, since the experience of having OMD is variable and individualized, any
treatment plan should be tailored to the individual based on his/her priorities and personal
concerns related to OMD. Finally, assessing psychosocial outcomes of BoNT-A injections
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should be ongoing in order to understand and to respond to evolving patient needs, goals, and
priorities (Baylor et al., 2007).

Chapter 5
5 Summary and Conclusions
This study explored the lived experiences of eight individuals receiving BoNT-A as a
treatment for OMD. The results of this study suggest that BoNT-A treatment has variable impact
and effect across domains related to quality of life, expectation and satisfaction with treatment,
speech production, and communicative participation; with some participants reporting positive
effects associated with receiving injections, and others reporting more negative or neutral
effect/impact. This information is extremely important in augmenting our understanding of the
impact of BoNT-A treatment, through a psychosocial lens and from the perspective of the
individual receiving this treatment.
This research adds novel information relating to the psychosocial consequences of
BoNT-A treatment in the management of OMD and builds on a small, but growing literature that
seeks to study the consequences and experiences of living with OMD. The results of this study
also have practical clinically-based utility because our findings can potentially aid clinicians in
targeting relevant and meaningful outcomes of treatment success. With expansion, this line of
research inquiry can aid in the eventual development of appropriate patient-reported outcome
measures that capture the issues relevant and meaningful to this clinical population.
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Appendices

Appendix A: Letter of Information
STUDY TITLE
The effects botulinum toxin A on speech intelligibility, levels of speech usage, communication
apprehension, self-perceived communication competence, communicative effectiveness, communicationrelated quality of life and the lived experiences of individuals with oromandibular dystonia.
PRINCIPAL INVESTIGATOR
Allyson Dykstra, Ph.D.
Assistant Professor
School of Communication Sciences and Disorders, Western University

CO-INVESTIGATOR
Dr. Mandar Jog, MD, FRCPC, Professor
Director, Movement Disorders Program
London Health Sciences Centre, University Campus and Western University

INTRODUCTION
This letter of information describes a research study and what you may expect if you decide to participate.
You should read the letter carefully and ask the person discussing this with you any questions that you
may have before making a decision whether or not to participate. This form contains important
information and telephone numbers, so you should keep this copy for future reference. If you decide not
to participate in this study, the decision will not be held against you and will not affect your treatment in
any way.
You are being asked to participate in this research study because you are an individual with
oromandibular dystonia (OMD). The purpose of this study is to investigate the effects of oromandibular
dystonia on your speech intelligibility (how understandable your speech is), your level of speech usage,
your level of apprehension or concern when you are communicating orally, your self-perceived
communicative competence, your effectiveness as a communicator in different social settings and your
quality of life as it relates to communication. An additional purpose of this study is to compare how the
Botox© injections you are receiving to manage your dystonia affects your speech intelligibility, your
communicative apprehension, communication effectiveness and communication-related quality of life.
We are also interested in learning about your experience of having oromandibular dystonia.
This study will involve 30 participants with OMD. Information about participants will be collected from
patient charts and person-to-person interviews by the principal experimenter or another designated
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member of the research team. This will include information about the participant’s date of birth, general
medical history, neurological history, and speech and hearing history.
This study will be conducted over two sessions, separated by approximately one month and lasting
approximately 40 minutes for the first visit and approximately 2 hours for the second visit. Both visits
will involve speech recordings of your voice. During this 10 minute recording period you will be asked to
read aloud a series of 57 single words and 11 sentences while being recorded with a microphone. Both
visits will also involve completing a series of six questionnaires that will look at how you use your speech
on a daily basis, your level of concern or apprehension when you are communicating orally, your selfperceived competence when communicating, your effectiveness as a communicator in different social
situations and your quality of life as it relates to your communication. It is anticipated that completion of
the questionnaires will take approximately 30 minutes. The second visit will involve an additional 60-90
minute one-time in-person interview with the researchers into order to learn more about your experiences
of living with oromandibular dystonia. During this interview we will ask you to share stories and
information about strategies you have used to help you participate in life activities due to having dystonia.
We want to hear about strategies that worked well and those that did not work well. In particular, we want
to hear about things that make you more or less confident about your participation in activities. We want
to hear your recommendations that you would give to other people in similar circumstances. You do not
need to answer any questions you do not want to answer. The interview will be audio-recorded. Only the
researchers will have access to the recording of the interview. The audio file would be stored on a secure
server at Western University.
The first visit will be completed during your scheduled clinic visit at the Movement Disorders Clinic. The
second visit will be scheduled approximately one month later to ensure that your Botox© treatment is
working optimally.
If you agree to participate you will be able to complete the first visit of the study directly following your
scheduled appointment time at the Movement Disorders Clinic in a separate testing room located within
University Hospital. For the second visit of the study you will be asked to come to the Principal
Investigator’s Lab in Elborn College at the University of Western Ontario for repeat administration of
questionnaires, speech recordings and the in-person interview. While at Elborn College, you will be
provided with free parking.
The experimental procedures will require very little physical effort, and there is no known discomfort or
risk involved in performing them. You will be seated in a comfortable chair throughout the procedures
and during the interview and you will be given rest breaks approximately every five minutes or more
frequently if required.
The procedures that will be used during this study are experimental in nature and will not provide any
direct benefit to the participant’s medical condition, however, it is anticipated that results from this study
may provide important information about the effect of oromandibular dystonia on speech intelligibility,
one’s perception of their apprehension when communicating orally, their level of speech usage, their
perception of how effective they are as communicators, and their quality of life as it relates to
communication. It may also provide important information about the effect of Botox© on speech
intelligibility, communication apprehension, communicative effectiveness and communication-related
quality of life. Financial compensation will not be provided upon completion of this study. Parking costs
over and above your regular clinic visit at the Movement Disorders Clinic will not be reimbursed. While
at Elborn College, you will be provided with free parking.
Participation in this study is voluntary. You may refuse to participate, refuse to answer any questions, or
withdraw from the study at any time with no effect on your future care.
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All of the information obtained in this study will be held in strict confidence. Your name and any
identifying information will be removed from the data. If the results of the study are published, your name
will not be used and no information that discloses your identity will be released or published.
Representatives of Western University’s Health Sciences Research Ethics Board may contact you or
require access to your study-related records to monitor the conduct of the research. You do not waive any
legal rights by signing the consent form.
Throughout the study, all confidential information and data will be preserved in a locked filing cabinet in
the Principal Investigator’s laboratory at Elborn College, Western University. All study materials will be
destroyed after 25 years.
If requested, you will be provided with a copy of any publication related to the results of this study when
it becomes available.
If you have any questions or would like additional information about this study, please contact Professor
Allyson Dykstra. If you have any questions about the conduct of this study or your rights as a research
subject you may contact Dr. David Hill.
If you agree to participate in this study, please sign the consent form on the next page.
Sincerely,
Allyson Dykstra, PhD Assistant Professor
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Appendix B: Consent Form
STUDY TITLE
The effects botulinum toxin A on speech intelligibility, levels of speech usage, communication
apprehension, self-perceived communication competence, communicative effectiveness, communicationrelated quality of life and the lived experiences of individuals with oromandibular dystonia.
PRINCIPAL INVESTIGATOR
Allyson Dykstra, Ph.D.
Assistant Professor
School of Communication Sciences and Disorders, Western University

CO-INVESTIGATOR
Dr. Mandar Jog, MD, FRCPC, Professor
Director, Movement Disorders Program
London Health Sciences Centre, University Campus and Western University

I have read the Letter of Information, have had the nature of the study explained to me and I agree to
participate. All questions have been answered to my satisfaction.

________________________

________________________

Signature of Research Subject

Printed Name

_______________________________

________________________

Signature of Person Obtaining Consent

Printed Name

________________
Date

_________________
Date
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Appendix C: Ethics Approval Notice
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Appendix D: Code Dictionary
1. Botox Injection:
a. Frequency: Number of times individuals receive a dosage, number of months in
between dosage, number of dosages
b. Injection site: BoNT-A needle injections at specific sites on the facial area
c. Physical Effects:
i. Effect on Muscle: lack of tension/or extra tense, loosened muscles,
tightness, deterioration of muscles
ii. Muscle Movement: lack of control or improved control, locking muscles,
tremor, freedom of movement
iii. BoNT-A Wearing off
2. Eating/drinking:
a. Eating Mechanics: fear of choking, avoidance of certain foods, food consistency,
keeping food/drink in mouth
b. Physical Effect on Eating: loss of taste, dry mouth, saliva and lubrication, pain
due to biting inside of mouth/ tongue
c. Social Aspect of Eating: self-consciousness, safety
d. Strategies to Improve Eating: saliva production
3. Facial Aesthetics: Facial alteration as a result of the injections, the effect of the needles,
the effect of the BoNT-A on the muscles
4. Good Story: Personal stories depicting positive or negative interactions/moments postBoNT-A injections
5. Job: Ability to work post- BoNT-A, loss of job as a result of the BoNT-A, type of job,
regaining job, personal values attributed to job
6. Pain:
a. Pain From Injection: swollen tongue, not able to breathe, swelling, pain/no pain
as a result of the injections, biting inside of mouth/ tongue as result of injection
b. Pain Post-Injection: from the facial movements post- BoNT-A injections, aches,
soreness, cuts in mouth, swelling
7. Personal Perspective: How participants view themselves post-injection, view of
disability and normalcy
8. Psychological effect: Emotional reaction as a result of receiving BoNT-A, shock,
happiness, disappointment, confidence, hopefulness, embarrassment, surprise, self-
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esteem, uncertainty, relief, self-consciousness, feeling intelligent or lacking intelligence,
sadness, frustration, fear, excitement, awareness, worry, stress, affect on QOL
9.

Resilience: Pushing through difficult situations, persevering, tackling physical and
emotional barriers, improving outlook, strong character traits, positive outlook

10. Social Aspects:
a. Participation in Social Activities/: Ability to interact in social settings (religious
settings, family gatherings)
b. Perspective of Others: Others perception of their treatment process
c. Relationships: Effect on Family and friends relationships post-treatment
11. Speech:
a. Communication: Ability to hold a conversation, to have meaningful
conversations and communicate in social and public and private settings, ability to
express emotions and opinions through speech
b. Fatigue: exerting effort to speak post-injection, less fatigue as a result of the
injections, less effort post-injection, tired from speaking too much, loss of speech
due to being tired
c. Intelligibility: Improved or worsened intelligibility, improvement/ or no
improvement of slurred speech, individuals understanding of participants speech,
and participants’ perspective on their speech
d. Speech Mechanics: Response rate, ability to speak, difficulty speaking,
pronunciation, Speech rate, strategies and word substitutions, enunciation,
formation of letters, loudness, initiating speech, speech production, voice change
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Appendix E: Reflexive Notes
Section 1: Qualitative Research: A New Avenue
Once I completed a course in qualitative methods, my social positioning as a researcher
became even more evident. What captured me most was how qualitative research had the ability
to humanize diverse lived experiences.
After immersing myself in qualitative literature, I became more aware of its
multidimensional nature. Qualitative research has the ability to present individual or collective
narratives and portray how these experiences shape the complexity of meaningful activities that
take place in day-to-day life. As I am studying Oromandibular dystonia, I must consider my
outsider status. Even though I do not struggle with the exact disorder the participants may face,
qualitative research allows me to share their consciousness at a human level. Qualitative research
has completely changed my outlook on my research and made me eager and motivated to
understand and empathize with the lived experiences of each participant.
My research was conducted using a phenomenological methodological approach. After
learning about phenomenology I realized that it would be the most appropriate methodology to
express participants’ experiences of receiving BoNT-A injections. I was able to analyze the
participants lived experiences and shed light on issues that were relevant to them.
After reading some more papers related to my research topic, I realized that my research
would be guided by an interpretivist paradigm. This was due to the fact that I was analyzing
previously transcribed interviews. I listened to the audio-recorded interviews to gain a deeper
connection with the participants and further immerse myself into their stories and experiences.
This paradigm allowed me to combine previous literature findings and the participants’ findings,
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to share the lived experience of OMD and the psychosocial impact of receiving BoNT-A
injections.
Section 2: Shared Consciousness
Prior to my research on OMD and BoNT-A, I began with an assumption that the majority
of the participants would describe it as a viable treatment. This assumption was further realized
in my neurological motor speech and disorders course. This course provided me with knowledge
on OMD, its symptoms and treatment methods. Understanding OMD was my first step in
appreciating the impact of BoNT-A on individuals. I gained an appreciation for the vast
influence it has on participants, by understanding the regions of the brain affected, the
symptoms, dystonic movements and effect on language and speech. I also acquired information
on the effect of treatment methods, including BoNT-A injections. This insight provided me with
an excellent platform to appreciate the effect of BoNT-A treatment, from a physical perspective.
Alongside the motor speech course, I was enrolled in a course on the International
Classification of Functioning (ICF) framework. This course allowed me to shift my
understanding of OMD and think about it from a comprehensive perceptive, which surpassed its
physical impact. Stepping back and trying to understand the impact of OMD from this
framework was difficult. I struggled with understanding the impact of OMD from a psychosocial
perspective, but this course allowed me to delve into previous qualitative papers and helped me
recognize how OMD and BoNT-A could impact an individual at all levels, from participation
and QoL to personal and environmental factors, and that this was not a linear or sequential
impact, but rather an interactive impact where each component could affect the other in
whichever way.
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My literature review results produced many papers on OMD and BoNT-A, from a
physical aspect, alongside some literature on emotional and social well-being, post-injection.
Although the research was sparse, it improved my understanding of OMD and BoNT-A
treatment. I had the impression that BoNT-A was a beneficial treatment, in terms of its impact on
improving QoL and social and communicative participation.
Section 3: Participant Experiences
Through the audio recorded interviews and transcripts, I gained insight into each
participants’ personality and experiences, through their own words. I was able to understand and
empathize with their struggles and improvements. Inherently, I began to compare the
participants’ responses to that of previous literature. I appreciated how phenomenology methods
allowed for a unique understanding of each participants story, as I compared my participants
remarks to former studies, which mainly acquired their results via questionnaires. Hearing the
participants’ stories made me realize the difficulties that they experienced. That realization
further emphasised the importance of filling in the research gap in OMD. Understanding the
participants’ experiences of OMD, prior to injection, allowed me to gauge the improvements, or
lack thereof, post-injections.
I composed a summary for each participant after I had listened to his or her interviews, to
gain an overall understanding about each participant’s experiences.
EP had very different results than I assumed. EP expressed that his muscles weakened
after receiving injections for 22 years. This was not something I anticipated, nor would it have
been something I could have understood, had I not been exposed to dysarthria in the motor
speech course.
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EP has been receiving BoNT-A for 22 years. EP receives BoNT-A in his eyes every 2-3
months, and gets injections in his jaw and neck. As a result of the injections, he
experiences deterioration of his eye jaw and neck muscles. EP also reports bruising at the
injection sites, and states that they are very painful. EP is uncertain of the effects of
BoNT-A and feels as though he can no longer recognize his voice. In recent years EP has
begun to have a fear choking, and is very careful when eating. BoNT-A still allows him
to travel, as he schedules his injections accordingly. Without BoNT-A, EP would be very
limited in his eye and jaw movements and expresses that the limitation would make him
feel handicapped. BoNT-A has prevented him from slipping into thoughts aiding in lower
self-esteem. BoNT-A injections allow EP to sit through a movie or have a conversation.
EP wishes his muscles did not deteriorate as a result of the BoNT-A and that they would
get better and be cured. EP is resilient and believes that he needs to accept the situation
he is in and move on. He does not allow himself to feel sorry for the situation he is in; he
tries to be happy and feels fortunate that at least he has BoNT-A. He does not feel
disabled with the BoNT-A injections.

NF seemed very happy with her changes. She expressed a very positive reaction to the
BoNT-A injections and often mentioned how it helped her QoL, communication and
participation. Her responses were what I anticipated, based on my limited understanding of
BoNT-A injections.
NF has been receiving BoNT-A for 8 years. NF receives injections in the tongue and
under her chin. Injections in her tongue cause swelling and pain. NF has a tendency to
bite her tongue as a result of the BoNT-A. After her first injection, she was shocked after

84
saying her first words, and felt as though it was a miracle. BoNT-A gave her confidence
and allowed her to go back to work 8 months post-injection. She is resilient and makes
light of her situation through jokes. 2 weeks Post-injection NF is careful of what to eat, as
she fears choking. In that time, NF will try to eat with people around her to make sure she
is not alone, in the event that she does choke. NF says that BoNT-A has allowed her to
eat more than she used to without contemplating what she can or cannot eat. Her speech
improved with the BoNT-A, and she believes that it makes her feel normal and allows her
to laugh, express her emotions and be social. BoNT-A has had a huge impact on her
communication with her family and she feels that it has taken her from disabled to abled.

JR was less expressive about his journey with BoNT-A; he discussed how the injections
helped him in social situations and improved his confidence. Contrary to my assumptions, JR felt
that BoNT-A did not assist in his speech production.
JR has been receiving BoNT-A injections for 3 months. JR had twitching eyes and
prominent jaw and lip movements that more so affected the left side of his face than the
right. These movements have calmed down after injection and as a result, he is less
worried and less embarrassed about his facial movements. BoNT-A has also helped JR’s
driving as the BoNT-A has reduced his eye twitches. The BoNT-A treatment has not
helped his speech, but JR feels that his QOL has been improved, and that the injections
helped his facial appearance, although his face is now sorer. JR is now more social as a
result of the BoNT-A injections. JR feels that BoNT-A has allowed him to be as normal
as possible.
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SP was also less expressive about his experience with receiving the BoNT-A injections.
As everyone mentioned specific things they wished BoNT-A would help, SP had an overall
expectation that it would help him get back to normal. Although his expectations were not met,
SP did express that BoNT-A helped with communication.
SP has been receiving BoNT-A for 11 years. SP receives injections in between his
eyelids, cheek, chin, lips, and jaw. SP injections sites feel sore. After his first injection,
SP states that there were no improvements, but his second injection helped with his lip
movements and his speech improved. His face used to draw down prior to BoNT-A, and
he would have to put in a lot of effort to speak. BoNT-A helped SP with his
communication, not only in the sense of stringing words together, but also in conveying
meaning. BoNT-A has eliminated barriers to communication for SP. SP expected that
BoNT-A would help him get back to normal, but was disappointed that it did not.

BR also seemed very happy with his BoNT-A treatment results. His resilience is one that
stood out, as he constantly made reference to pushing through situations. His experiences echoed
previous literature on speech intelligibility.
BR has been receiving BoNT-A for 3 years. BR receives injections in his jaw, and collar
muscle. BoNT-A has helped his slurred speech and his intelligibility. BR feels that his
response rate is faster after the injections and that he does not require the constant effort
that he once needed. This has helped BR’s phone job. BR no longer overthinks how he
should answer a question. BR feels that these improvements are important to him.
Following BoNT-A injections, BR notices that he has a dry mouth and has a hard time
keeping food in his mouth. BR’s perspective on BoNT-A is “if it works it works, if it
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doesn’t it doesn’t”. BR is very resilient. He believes that if BoNT-A did not exist he
would try to find another solution.

ST had been receiving the injections for the least amount of time. She had not seen any
dramatic changes in terms of speech, but did mention her improvements in participation and
overall mood. The improvements in participation align with previous research findings.
ST has been receiving BoNT-A for 3 months. ST receives BoNT-A in her mouth and
jaw. The BoNT-A has stopped her jaw from locking, and has allowed her to sneeze
properly. ST has not found any significant changes to her speech with the injections.
BoNT-A injections have allowed ST to want to go out and be with people. She feels as
though she no longer has to worry and is happy with the changes the BoNT-A has
provided her, it makes her feel good to see improvements. She wishes it helped her jaw a
little more, but is not expecting miracles.

FI shared the most varied experiences, as she was unsure of the impact of the injections.
FI felt as though the injections were altering her face in a negative manner, this was different
than my expectations, as I was assuming the BoNT-A would help improve facial aesthetics. On
the other hand, she also explains that facial twitching was improved post-BoNT-A injections.
FI has been receiving BoNT-A for 21 years. She receives injections around her mouth, in
her neck and jaw. As a result of BoNT-A, FI experience dry mouth and loses her sense of
taste a week post-injection. The injection sometimes makes her mouth open too wide or
causes her mouth to be clenched closed. As a result, she finds it difficult to chew and is
now eating mashed foods. FI is unsure how BoNT-A has helped and is worried that there
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is not an overall plan for her injections. FI feels that there is almost a psychological
effect, where she receives BoNT-A and her expectation is that something will change,
whatever that change is, she is not sure. FI compares photographs of her face and feels
that she looks different post-BoNT-A, that her face looks less relaxed. FI finds that her
speech might be better, but her speech sounds weird now and she cannot say precisely
how BoNT-A affects her speech. She thought that BoNT-A would be more helpful. FI
feels like she is just getting BoNT-A for cosmetics now. FI does not feel that BoNT-A
has affected her ADL and she still enjoys travelling. FI finds that BoNT-A helps her
confidence for the first weeks before it wears off, she feels more in control. Also, after
receiving it she is not worried as much about facial twitching in social settings and she
feels she can be more personable before BoNT-A wears off.

GM, similarly to FI, also experienced negative impacts from the BoNT-A, on facial
aesthetics. This increased his self-consciousness post-injections. The pain he experienced postinjection also stood out, as he described waking up with his lips stuck to his teeth, due to dry
mouth, which further resulted in micro-tears alongside his inner lip. Nevertheless, he was still
very positive about the benefits of BoNT-A and expressed resiliency.
GM has been receiving BoNT-A for 3 years. GM receives BoNT-A in corners of his
mouth. BoNT-A helped counteract the drooping corners of his lips (making a grimacing
face). As a result of the BoNT-A, GM has red marks on the corners of his mouth, and this
is something that bugs him, and something that he notices and feels that everyone notices
as well. GM does not want to look like the Joker. GM does feel that the BoNT-A makes
things better and helps ease the effort it takes to speak. GM is an optimistic person and
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does not think BoNT-A has affected his thinking about life or philosophy. GM is resilient
and tries not to worry about things if they are not life or death. Although BoNT-A affects
his facial appearance, he finds that his response rate is faster and states that this is more
important to him. With BoNT-A he is not afraid to talk, and he feels more confident in
conversations, whether one-on-one or in a group. He also does not have to exert a lot of
effort when speaking. GM does find that the BoNT-A affects his eating and his mouth
tends to dry out. He is cautious about his appearance and finds it hard to get food off his
teeth when he is eating, as he does not want to have his tongue sticking out of his mouth,
so he makes sure he always has water and is eating in a certain way. GM feels that
BoNT-A gave him confidence and that it is a “Godsend”. GM wishes that the BoNT-A
would help with controlling his mouth from moving around. BoNT-A has changed his
life and he would be afraid if it was banned.
Section 4: Code Composition
I have developed codes on Dedoose for each transcript. I highlighted the results related to
the treatment of OMD with BoNT-A. I extracted excerpts from the transcripts, and correlated
each participants experience into a code. Everything the participants mentioned about the BoNTA injections was coded. Common concepts were continuously emerging, alongside varying
perspectives and experiences.
Participants discussed their communication in private and in public settings and their
ability to hold a conversation and adequately express their emotions. I empathized with that
concept of struggling to relay emotions and the relief of being able to do so post-injections. This
was not something I read about or considered as an effect post-injection. There were a lot of
discrepancies between subjects. I noticed that some were even experiencing discrepancies
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throughout their own treatment experiences, e.g. a participant may express that at time speech
was improved with BoNT-A, and then the same participant would express that speaking was
difficult or does not “correct” everything.
Facial alterations were also another topic being raised, again there were varying
responses, which I had not considered. I had not read about negative changes to aesthetics
throughout my literature review. I had these assumptions that BoNT-A would help dystonic
movements, rather than cause facial alterations, such as GM experienced. Feeling tired was
another concept that was raised, in terms of effortful speaking or lack of effort post-injections.
The number of injections received, also varied between participants and the struggle with
perfecting dosages and time of dosage was a problem that was raised, as well as where the
participants were receiving the injection. Some were receiving it in the tongue, jaw, neck, etc.
I also included a coding component for good stories. Participants were expressing some
positive or negative stories that they have gone through post-injections. The process of
phenomenology research allowed me to be able to incorporate these findings in my data
collection and this improved my understanding of the patient’s experiences and struggles,
through their own words. The nature of phenomenology research allowed me to gain a better
understanding of the participants experiences’ with pain. Unlike other research methodologies,
phenomenology allowed the participant to elaborate on their experiences. Previous research,
used questionnaires as a primary method of data collection, which unfortunately did not provide
participants the opportunity to elaborate on their responses.
Understanding the perceptive of each participant was incredibly eye-opening. Although
some were taking BoNT-A for a long time, FI in particular seemed uncertain of her
improvements post-injections. It was interesting to see how different her reaction was to the
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treatments in contrast to NF, who had an overwhelmingly positive experience. Also, how
participants viewed themselves post-injections was a new concept. NF and JR both expressed
feeling normal post-injections, which was a concept I had not encountered in the literature.
The physical effects and impact of BoNT-A was something I was familiar with. The
participants echoed some of what I had learned about BoNT-A and OMD. The psychological
effects were also fascinating and echoed some of the previous research on this topic. Each
emotional outcome experienced by the participants was very eye-opening. The unfortunate part
was learning about the negative emotional experiences, which were a result of expectations that
were not met.
The social aspects raised were also ones that I encountered throughout previous papers.
They were similar in regards to the improved impact that BoNT-A had on social participation.
Speech improvement was another concept raised. The participants’ responses sometimes
echoed previous findings, but other times were the complete opposite. I did not expect many
negative responses, but with the motor speech course and previous literature, I could appreciate
how the participants could have negative responses. The participants positive outlook persisted,
even with the negative side effects.
Initially, these concepts produced 15 codes. Through feedback from my supervisor and
advisory members, I narrowed the 15 down to 11 codes with sub-codes. 1) Regarding injections,
which included the frequency, site and physical effects (effect on muscle, and wearing off), 2)
Eating and drinking with sub-codes on mechanics and physical effects of eating, social aspects of
eating and strategies that improved eating. 3) Facial aesthetics, 4) Good story, 5) Job, 6) Pain,
with sub-codes on pain from injection and pain post-injection. 7) Personal perspective (how
participants viewed themselves) 8) Psychological effect, 9) Resilience, 10) Social aspects with
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sub-codes on participation in social activities, perceptive of others, and relationships, lastly, 11)
Speech with sub-codes, which included communication, fatigue, intelligibility and speech
production.
Section 5: Creation of Themes
I began to group the codes into themes that reflected the participants’ struggles and
improvements post-injections. I struggled with making the themes, as I wanted to make sure I
completely captured all the participants’ experiences and relayed an accurate depiction of what
the participants expressed.
Excerpts that touched on speech and communication were grouped together. The speech
aspect tied into the social aspect of communication and participation, which included changes in
participants speech, both mechanic changes and intelligibility changes and the social and
emotion effect this had on participants. Sub-theme regarding changes in participants speech, such
as response rate, intelligibility, articulation and pronunciation, which either improved or stayed
the same post-BoNT-A injections, were also included. The second sub-theme was on
participation and changes in participation that were experienced. Participants described their
ability to interact in social settings (religious settings, friend and family gatherings), and ability
to participate in their jobs and daily activities, post-BoNT-A injections.
Another theme was based on perceptive. Participants shared their perspectives on how
BoNT-A affected them emotionally, as well as its effect on their perception of themselves and
how other perceived them. The first sub-theme was the concept of feeling “normal” and less
disabled post-injection, the other sub-themes were on the positive psychological effects, and
lastly, the negative psychological effects. The third theme explored how BoNT-A changed the
participants’ experiences. This included the everyday experiences that changed as a result of the
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injections, and how these changes affected participants QOL and day-to-day activities. The subthemes were eating is not the same, which included topics on choking and food consistency and
dry mouth (I tied in a lot of the physical effects here), another sub-theme was face alteration,
both positive and negative changes. The next sub-theme was the experience of pain and finally,
the last sub-theme was effort and fatigue.
After consulting my supervisor and advisory members, we narrowed down the themes
and reorganized them to better represent the psychosocial impact of BoNT-A. The themes were
reorganized, the first Botox has changed me, The sub-theme I feel normal again (tying in their
perspective of themselves), then the sub-theme I feel appreciative of what Botox does for me (the
positive impact), and finally, Botox doesn’t fix everything (the negative impact). The next theme
What communication is like for me, the first sub-theme My speech has changed, and the
second sub-theme, I can now participate. The third theme Botox has changed my experiences,
which incorporated the sub-theme My eating has changed, and My face looks different, I am
experiencing pain, I am experiencing fatigue.
After another review of the themes, pain and fatigue were incorporated into the previous
sub-themes, e.g. pain in receiving injections was a negative experience or a positive experience,
(pain was relieved post-injections). This sub-theme was included in the theme, Botox has
changed me and my experiences and sub-theme, I feel appreciative of what Botox does for me
and the sub-theme Botox doesn’t fix everything. Also, fatigue, as a result of injection, was always
discussed in the context of speech. This was then incorporated into that theme, What
communication is like for me and the sub-theme My speech has changed.
The final consensus for the themes was to remove the sub-theme regarding eating, as it
was focused on physical effects, rather than psychosocial effects of BoNT-A injections. Then the
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sub-theme regarding facial aesthetics (My face looks different) was placed within theme Botox
has changed me and my experiences, alongside the sub-theme, I feel appreciative of what
Botox does for me, and Botox doesn’t fix everything. The second theme was, What
communication is like for me with the sub-themes My speech has changed and I can now
participate. The excerpts corresponding to each theme were grouped and expanded on and
explained in the results section of this paper.
Section 6: Comparison of Findings to Previous Literature
The discussion process was more difficult than I anticipated. I struggled with the
organization and logistical flow, of comparing the results. I grouped together all the research
articles that discussed each section of the results and compared the findings. There were no
research articles that discussed the concept of feeling “normal” post-injection or papers on the
negative changes to facial aesthetics. These findings were difficult to find in the research on
OMD, as well as research in other types of motor speech disorders. The discussion section of this
paper elaborated on other speech disorders to provide a wholesome understanding of the
psychosocial impact of BoNT-A. Similar research on speech disorders allowed for a
comprehensive understanding of the psychosocial impact of BoNT-A, that previous participants
expressed.
The discussion section of this paper verified the importance of conducting further
research in the area of OMD and BoNT-A, and the importance of incorporating the participants’
experiences, almost as decision-makers, in future research to further improve assessments and
treatment measures. I feel extremely lucky to be provided the opportunity to conduct research in
the topic of OMD and add to the ever growing research in this field. The participants’ stories and
lived experiences were a pleasure to listen to.
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